"ID","URL","PDF","Country","Province","Date","Trial status","Design","Blinding","Arms","COVID-19 status","Severity","Patient setting","Outcome","Treatment","Size"
"NCT04359095","https://ClinicalTrials.gov/show/NCT04359095",NA,"Colombia","Huila","2020-Apr","Not Recruiting","Randomized","Open-Label",4,"Yes","Mixed","Hospitalized",NA,"HCQ, LPV/r, AZT",1600
"NCT04321993","https://ClinicalTrials.gov/show/NCT04321993",NA,"Canada","Nova Scotia","2020-Mar","Recruiting","Non-Randomized","Open-Label",3,"Confirmed","Mixed","Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, SpO2","LPV/r, HCQ, Baricitinib, Sarilumab",1000
"NCT04361942","https://ClinicalTrials.gov/show/NCT04361942",NA,"Spain","Valladolid","2020-Apr","Not Recruiting","Randomized","Triple",2,"Yes","Severe","ICU","Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","Stem cell",24
"NCT04328285","https://ClinicalTrials.gov/show/NCT04328285",NA,"France","Paris","2020-Mar","Recruiting","Randomized","Triple",4,"Healthy",NA,"Healthcare Workers","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Treatment-emergent Adverse Events","HCQ, LPV/r,",1200
"NCT04330638","https://ClinicalTrials.gov/show/NCT04330638",NA,"Belgium","Brussels","2020-Apr","Recruiting","Randomized","Open-Label",4,"Confirmed Or Suspected","Severe","Hospitalized And ICU","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, White Blood Cell Count, Neutrophils, Platelet Count, PaO2-FiO2, Radiographic Findings, Hypoxia","Anakinra, siltuximab, TCZ",342
"NCT04330638","https://ClinicalTrials.gov/show/NCT04330638",NA,"Belgium","Antwerp","2020-Apr","Recruiting","Randomized","Open-Label",4,"Confirmed Or Suspected","Severe","Hospitalized And ICU","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, White Blood Cell Count, Neutrophils, Platelet Count, PaO2-FiO2, Radiographic Findings, Hypoxia","Anakinra, siltuximab, TCZ",342
"NCT04342182","https://ClinicalTrials.gov/show/NCT04342182",NA,"Netherlands","Zuid-Holland","2020-Apr","Recruiting","Randomized","Single",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, PaO2-FiO2","Plasma",426
"NCT04342182","https://ClinicalTrials.gov/show/NCT04342182",NA,"Netherlands","Amsterdam","2020-Apr","Recruiting","Randomized","Single",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, PaO2-FiO2","Plasma",426
"NCT04343092","https://ClinicalTrials.gov/show/NCT04343092",NA,"Iraq","Baghdad","2020-Apr","Recruiting","Randomized","Double",4,"Yes","Mixed","Mixed","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, Serious Adverse Events, SpO2","HCQ, Ivermectin",50
"NCT04351724","https://ClinicalTrials.gov/show/NCT04351724",NA,"Austria","Tirol","2020-Apr","Recruiting","Randomized","Open-Label",9,"Yes","Mixed","Mixed",NA,"HCQ, LPV/r, Multiple others",500
"NCT04351724","https://ClinicalTrials.gov/show/NCT04351724",NA,"Austria","Vienna","2020-Apr","Recruiting","Randomized","Open-Label",9,"Yes","Mixed","Mixed",NA,"HCQ, LPV/r, Multiple others",500
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","California","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Colorado","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Connecticut","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Hawaii","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Illinois","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Indiana","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Iowa","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Louisiana","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Maine","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Maryland","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Massachusetts","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Michigan","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Minnesota","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Montana","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","New Hampshire","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","New Jersey","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","New York","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","North Carolina","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Ohio","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Oregon","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Pennsylvania","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Rhode Island","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","South Carolina","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Texas","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Utah","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Virginia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United States","Washington","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"China","Beijing","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"France","Paris","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Germany","Berlin","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Germany","Hamburg","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Germany","Schleswig-Holstein","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"China","Hong Kong","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Bergamo","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Brescia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Cremona","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Milano","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Rome","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Padova","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Parma","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Pavia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Piacenza","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Italy","Roma","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Japan","Kanagawa","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Japan","Tokyo","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"South Korea","Daegu","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"South Korea","Seoul","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Netherlands","Amsterdam","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Singapore","Singapore","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Asturias","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Madrid","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Barcelona","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Bizkaia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Spain","Sevilla","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Sweden","Stockholm","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Switzerland","Bern","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Taiwan","Taipei","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"Taiwan","Taipei City","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Edinburgh","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Glasgow","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","London","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Liverpool","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Manchester","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Plymouth","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292899","https://ClinicalTrials.gov/show/NCT04292899",NA,"United Kingdom","Sheffield","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Adverse Events","Remdesivir",6000
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","California","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Colorado","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Connecticut","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Hawaii","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Illinois","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Indiana","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Iowa","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Louisiana","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Maine","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Maryland","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Massachusetts","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Michigan","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Minnesota","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Montana","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","New Hampshire","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","New Jersey","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","New York","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","North Carolina","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Ohio","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Oregon","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Pennsylvania","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Rhode Island","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","South Carolina","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Texas","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Utah","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Virginia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United States","Washington","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"China","Beijing","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"France","Paris","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Germany","Berlin","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Germany","Hamburg","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Germany","Schleswig-Holstein","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"China","Hong Kong","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Bergamo","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Brescia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Cremona","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Milano","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Rome","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Padova","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Parma","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Pavia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Piacenza","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Italy","Roma","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Japan","Kanagawa","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Japan","Tokyo","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"South Korea","Daegu","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"South Korea","Seoul","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Netherlands","Amsterdam","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Singapore","Singapore","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Asturias","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Madrid","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Barcelona","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Bizkaia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Spain","Sevilla","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Sweden","Stockholm","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Switzerland","Bern","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Taiwan","Taipei","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"Taiwan","Taipei City","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","London","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Edinburgh","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Glasgow","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Liverpool","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Manchester","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Plymouth","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04292730","https://ClinicalTrials.gov/show/NCT04292730",NA,"United Kingdom","Sheffield","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Non-invasive Ventilation, Treatment-emergent Adverse Events","Remdesivir",1600
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","California","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Colorado","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Illinois","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Louisiana","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Massachusetts","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Minnesota","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","New Jersey","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","New York","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","North Carolina","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Texas","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United States","Washington","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Canada","Ontario","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Canada","Quebec","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Denmark","Copenhagen","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"France","Vendee","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"France","Paris","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Germany","Berlin","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Italy","Napoli","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Italy","Roma","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Italy","Bergamo","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Italy","Milano","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Italy","Rome","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Italy","Pavia","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Netherlands","Amsterdam","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Netherlands","Utrecht","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Spain","Barcelona","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"Spain","Madrid","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United Kingdom","Glasgow","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United Kingdom","Leeds","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United Kingdom","London","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United Kingdom","Manchester","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04320615","https://ClinicalTrials.gov/show/NCT04320615",NA,"United Kingdom","Salford","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Hyper-Inflammation, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Platelet Count, D-Dimer, Creatinine Phosphokinase, Bilirubin, Glucose, Antibodies, PaO2-FiO2, SpO2, Radiographic Findings, Lung Inflamation, Hypoxemia, Quality of Life","TCZ",330
"NCT04332107","https://ClinicalTrials.gov/show/NCT04332107",NA,"United States","California","2020-Apr","Not Recruiting","Randomized","Quadruple",2,"Confirmed",NA,"Outpatients","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Dyspnea, PaO2-FiO2","Azithromycin",2271
"NCT04335071","https://ClinicalTrials.gov/show/NCT04335071",NA,"Switzerland","Bern","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism","TCZ",100
"NCT04335071","https://ClinicalTrials.gov/show/NCT04335071",NA,"Switzerland","Vaud","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism","TCZ",100
"NCT04335071","https://ClinicalTrials.gov/show/NCT04335071",NA,"Switzerland","Zurich","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism","TCZ",100
"NCT04335305","https://ClinicalTrials.gov/show/NCT04335305",NA,"Spain","Barcelona","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, ALT, AST, Albumin, Bilirubin, Glucose, SpO2","TCZ, pembrolizumab",24
"NCT04335305","https://ClinicalTrials.gov/show/NCT04335305",NA,"Spain","Madrid","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, ALT, AST, Albumin, Bilirubin, Glucose, SpO2","TCZ, pembrolizumab",24
"NCT04335305","https://ClinicalTrials.gov/show/NCT04335305",NA,"Spain","Valencia","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, White Blood Cell Count, Lymphocyte Count, Platelet Count, Hemoglobin, ALT, AST, Albumin, Bilirubin, Glucose, SpO2","TCZ, pembrolizumab",24
"NCT04343976","https://ClinicalTrials.gov/show/NCT04343976",NA,"United States","Massachusetts","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, SpO2, Respiratory Rate","Interferon Therapy",20
"NCT04335552","https://ClinicalTrials.gov/show/NCT04335552",NA,"United States","North Carolina","2020-Apr","Recruiting","Randomized","Open-Label",3,"Presumed","Mixed","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2","HCQ, azithromycin",500
"NCT04344379","https://ClinicalTrials.gov/show/NCT04344379",NA,"France","Paris","2020-Apr","Recruiting","Randomized","Double",3,"No","Non-severe","Healthcare Workers","Viral Load or Clearance","HCQ, azithromycin",900
"NCT04351516","https://ClinicalTrials.gov/show/NCT04351516",NA,"Germany","Berlin","2020-Apr","Recruiting","Randomized","Quadruple",2,"Yes","Mixed","Mixed",NA,"HCQ",350
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Arizona","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","California","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Colorado","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Florida","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Kentucky","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Louisiana","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Maine","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Massachusetts","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Michigan","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Mississippi","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","New York","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","North Carolina","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Ohio","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Oregon","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Pennsylvania","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","South Carolina","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Tennessee","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Texas","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Utah","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Virginia","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04332991","https://ClinicalTrials.gov/show/NCT04332991",NA,"United States","Washington","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"HCQ",510
"NCT04334265","https://ClinicalTrials.gov/show/NCT04334265",NA,"China","Anhui","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Unspecified","Unclear",NA,"Traditional Chinese Medicine",750
"NCT04334265","https://ClinicalTrials.gov/show/NCT04334265",NA,"China","Hubei","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Unspecified","Unclear",NA,"Traditional Chinese Medicine",750
"NCT04334265","https://ClinicalTrials.gov/show/NCT04334265",NA,"China","Zhejiang","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Unspecified","Unclear",NA,"Traditional Chinese Medicine",750
"NCT04333589","https://ClinicalTrials.gov/show/NCT04333589",NA,"China","Anhui","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Favipiravir",210
"NCT04333589","https://ClinicalTrials.gov/show/NCT04333589",NA,"China","Hubei","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Favipiravir",210
"NCT04333589","https://ClinicalTrials.gov/show/NCT04333589",NA,"China","Zhejiang","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Favipiravir",210
"NCT04324606","https://ClinicalTrials.gov/show/NCT04324606",NA,"United Kingdom","Southampton","2020-Mar","Recruiting","Randomized","Single",3,"Healthy","None","Healthy",NA,"Vaccine",1112
"NCT04324606","https://ClinicalTrials.gov/show/NCT04324606",NA,"United Kingdom","London","2020-Mar","Recruiting","Randomized","Single",3,"Healthy","None","Healthy",NA,"Vaccine",1112
"NCT04324606","https://ClinicalTrials.gov/show/NCT04324606",NA,"United Kingdom","Bristol","2020-Mar","Recruiting","Randomized","Single",3,"Healthy","None","Healthy",NA,"Vaccine",1112
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Canada","Ottawa","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Sarilumab",300
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"France","Paris","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Sarilumab",300
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Germany","Berlin","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Sarilumab",300
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Israel","Jerusalem","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Sarilumab",300
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Italy","Milano","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Sarilumab",300
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Italy","Modena","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Sarilumab",300
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Italy","Parma","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Sarilumab",300
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Japan","Tokyo","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Sarilumab",300
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Russia","Moscow","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Sarilumab",300
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Spain","Barcelona","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Sarilumab",300
"NCT04327388","https://ClinicalTrials.gov/show/NCT04327388",NA,"Spain","Madrid","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Sarilumab",300
"NCT04324463","https://ClinicalTrials.gov/show/NCT04324463",NA,"Canada","Ontario","2020-Mar","Recruiting","Randomized","Open-Label",3,"Confirmed",NA,NA,"Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Azithromycin ,  HCQ",1500
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"United States","Massachusetts","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Non-severe","Outpatients","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2, SpO2","HCQ",210
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"France","Paris","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Non-severe","Outpatients","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2, SpO2","HCQ",210
"NCT04333654","https://ClinicalTrials.gov/show/NCT04333654",NA,"Netherlands","Groningen","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Non-severe","Outpatients","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-6, Tumor Necrosis Factor (Any), D-Dimer, Antibodies, PaO2-FiO2, SpO2","HCQ",210
"NCT04346446","https://ClinicalTrials.gov/show/NCT04346446",NA,"India","Delhi","2020-Apr","Recruiting","Randomized","Open-Label",3,"Yes","Severe","Hospitalized",NA,"Plasma",20
"NCT04336410","https://ClinicalTrials.gov/show/NCT04336410",NA,"United States","Missouri","2020-Apr","Recruiting","Non-Randomized","Open-Label",2,"Healthy","Non-severe","Healthy Volunteer","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Vaccine",40
"NCT04336410","https://ClinicalTrials.gov/show/NCT04336410",NA,"United States","Pennsylvania","2020-Apr","Recruiting","Non-Randomized","Open-Label",2,"Healthy","Non-severe","Healthy Volunteer","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Vaccine",40
"NCT04348370","https://ClinicalTrials.gov/show/NCT04348370",NA,"United States","Massachusetts","2020-Apr","Not Recruiting","Randomized","Double",2,"No","Non-severe","Healthcare Workers",NA,"BCG Vaccine",700
"NCT04348370","https://ClinicalTrials.gov/show/NCT04348370",NA,"United States","Texas","2020-Apr","Not Recruiting","Randomized","Double",2,"No","Non-severe","Healthcare Workers",NA,"BCG Vaccine",700
"NCT04357808","https://ClinicalTrials.gov/show/NCT04357808",NA,"Spain","Madrid","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Sarilumab",30
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","Alberta","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Dyspnea, Treatment-emergent Adverse Events","LPV/r",440
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","British Columbia","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Dyspnea, Treatment-emergent Adverse Events","LPV/r",440
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","Ontario","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Dyspnea, Treatment-emergent Adverse Events","LPV/r",440
"NCT04330690","https://ClinicalTrials.gov/show/NCT04330690",NA,"Canada","Quebec","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Fever, Dyspnea, Treatment-emergent Adverse Events","LPV/r",440
"NCT04334980","https://ClinicalTrials.gov/show/NCT04334980",NA,"Canada","British Columbia","2020-Apr","Not Recruiting","Randomized","Triple",2,"Healthy","Non-severe","Healthy","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Platelet Count, Creatinine Phosphokinase, Prothrombin, ALT, AST, Bilirubin, Glucose","Vaccine",84
"NCT04334980","https://ClinicalTrials.gov/show/NCT04334980",NA,"Canada","Nova Scotia","2020-Apr","Not Recruiting","Randomized","Triple",2,"Healthy","Non-severe","Healthy","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Platelet Count, Creatinine Phosphokinase, Prothrombin, ALT, AST, Bilirubin, Glucose","Vaccine",84
"NCT04348474","https://ClinicalTrials.gov/show/NCT04348474",NA,"Brazil","Brasilia","2020-Apr","Suspended","Single-Arm","Open-Label",1,"Yes","Non-severe","Outpatients",NA,"HCQ, azithromycin",200
"NCT04329572","https://ClinicalTrials.gov/show/NCT04329572",NA,"Brazil","Brasilia","2020-Apr","Suspended","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospitalized","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, SpO2","HCQ",400
"NCT04345601","https://ClinicalTrials.gov/show/NCT04345601",NA,"United States","Texas","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Yes","Severe","ICU","Viral Load or Clearance","Stem Cells",30
"NCT04339712","https://ClinicalTrials.gov/show/NCT04339712",NA,"Greece","Athens","2020-Apr","Recruiting","Non-Randomized","Open-Label",2,"Yes","Severe","Mixed","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Anakinra, TCZ",40
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Madrid","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Alicante","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Asturias","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Barcelona","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Las Palmas","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","La Rioja","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Murcia","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Navarra","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Valencia","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Alava","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Albacete","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Burgos","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Cuenca","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Granada","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Palencia","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Salamanca","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Segovia","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Sevilla","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Valladolid","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04334928","https://ClinicalTrials.gov/show/NCT04334928",NA,"Spain","Zaragoza","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy","Non-severe","Healthcare Workers","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emtricitabine/tenofovir, HCQ",4000
"NCT04335084","https://ClinicalTrials.gov/show/NCT04335084",NA,"United States","California","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Healthy","Non-severe","Healthcare Workers","Viral Load or Clearance, Treatment-emergent Adverse Events","HCQ, vitamins",600
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Distrito Federal","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Severe","Hospitalized",NA,"Azithromycin ,  HCQ",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Espirito Santo","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Severe","Hospitalized",NA,"Azithromycin ,  HCQ",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Minas Gerais","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Severe","Hospitalized",NA,"Azithromycin ,  HCQ",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Para","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Severe","Hospitalized",NA,"Azithromycin ,  HCQ",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Brasilia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Severe","Hospitalized",NA,"Azithromycin ,  HCQ",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Rio Grande Do Norte","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Severe","Hospitalized",NA,"Azithromycin ,  HCQ",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Rio Grande Do Sul","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Severe","Hospitalized",NA,"Azithromycin ,  HCQ",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Brazil","Santa Catarina","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Severe","Hospitalized",NA,"Azithromycin ,  HCQ",440
"NCT04321278","https://ClinicalTrials.gov/show/NCT04321278",NA,"Israel","Jerusalem","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Severe","Hospitalized",NA,"Azithromycin ,  HCQ",440
"NCT04329611","https://ClinicalTrials.gov/show/NCT04329611",NA,"Canada","Alberta","2020-Apr","Recruiting","Single-Arm","Triple",1,"Confirmed",NA,"Outpatients","Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","HCQ",1660
"NCT04343768","https://ClinicalTrials.gov/show/NCT04343768",NA,"Iran","Tehran","2020-Apr","Completed","Randomized","Open-Label",4,"Yes","Mixed","Mixed","Mortality, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","HCQ, LPV/r, IFN",60
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Alberta","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Yes","Mixed","Hospitalized",NA,"Plasma",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","British Columbia","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Yes","Mixed","Hospitalized",NA,"Plasma",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Manitoba","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Yes","Mixed","Hospitalized",NA,"Plasma",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Ontario","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Yes","Mixed","Hospitalized",NA,"Plasma",1200
"NCT04348656","https://ClinicalTrials.gov/show/NCT04348656",NA,"Canada","Quebec","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Yes","Mixed","Hospitalized",NA,"Plasma",1200
"NCT04339426","https://ClinicalTrials.gov/show/NCT04339426",NA,"United States","Arizona","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Moderate/severe","Mixed","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious Adverse Events, PaO2-FiO2, Respiratory Rate","Atovaquorine, AZT",25
"NCT04348435","https://ClinicalTrials.gov/show/NCT04348435",NA,"United States","Texas","2020-Apr","Recruiting","Randomized","Quadruple",2,"No","Non-severe","Healthcare Workers",NA,"Stem Cells",100
"NCT04328493","https://ClinicalTrials.gov/show/NCT04328493",NA,"Vietnam","Hanoi","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized",NA,"HCQ",250
"NCT04328493","https://ClinicalTrials.gov/show/NCT04328493",NA,"Vietnam","Ho Chi Minh City","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized",NA,"HCQ",250
"NCT04351919","https://ClinicalTrials.gov/show/NCT04351919",NA,"Tunisia","Tunis","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Yes","Non-severe","Mixed",NA,"HCQ, azithromycin",400
"NCT04341389","https://ClinicalTrials.gov/show/NCT04341389",NA,"China","Hubei","2020-Apr","Not Recruiting","Randomized","Double",2,"Negative","Non-severe","Healthy","Viral Load or Clearance","Vaccine",500
"NCT04333914","https://ClinicalTrials.gov/show/NCT04333914",NA,"France","Paris","2020-Apr","Recruiting","Randomized","Open-Label",4,"Confirmed Or Suspected",NA,NA,"Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin","Chloroquine analog, nivolumab, TCZ",273
"NCT04349228","https://ClinicalTrials.gov/show/NCT04349228",NA,"Tunisia","Tunis","2020-Apr","Not Recruiting","Randomized","Single",2,"No","Non-severe","Healthcare Workers",NA,"HCQ",530
"NCT04321174","https://ClinicalTrials.gov/show/NCT04321174",NA,"Canada","British Columbia","2020-Mar","Recruiting","Randomized","Single",2,"Healthy (Exposed)","None","Healthy (Exposed)","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Other Mild Symptoms, Adverse Events, Quality of Life, Distress","LPV/r",1220
"NCT04321174","https://ClinicalTrials.gov/show/NCT04321174",NA,"Canada","Ontario","2020-Mar","Recruiting","Randomized","Single",2,"Healthy (Exposed)","None","Healthy (Exposed)","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Other Mild Symptoms, Adverse Events, Quality of Life, Distress","LPV/r",1220
"NCT04349371","https://ClinicalTrials.gov/show/NCT04349371",NA,"United States","New York","2020-Apr","Recruiting","Randomized","Quadruple",2,"No","Non-severe","Healthcare Workers",NA,"HCQ",350
"NCT04350671","https://ClinicalTrials.gov/show/NCT04350671",NA,"Iran","Tehran","2020-Apr","Recruiting","Randomized","Triple",3,"Confirmed","Severe","Hospitalized",NA,"IFN, HCQ, LPV/r,",40
"NCT04350684","https://ClinicalTrials.gov/show/NCT04350684",NA,"Iran","Tehran","2020-Apr","Recruiting","Randomized","Triple",5,"Confirmed","Mixed","Mixed",NA,"IFN, HCQ, LPV/R, Umifenovir",40
"NCT04331795","https://ClinicalTrials.gov/show/NCT04331795",NA,"United States","Illinois","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","TCZ",50
"NCT04348877","https://ClinicalTrials.gov/show/NCT04348877",NA,"Egypt","Cairo","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Yes","Severe","Hospitalized",NA,"Plasma",20
"NCT04349241","https://ClinicalTrials.gov/show/NCT04349241",NA,"Egypt","Cairo","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Yes","Non-severe","Mixed",NA,"FVP",100
"NCT04350931","https://ClinicalTrials.gov/show/NCT04350931",NA,"Egypt","Cairo","2020-Apr","Not Recruiting","Randomized","Single",2,"No","Non-severe","Healthcare Workers",NA,"BCG Vaccine",900
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","California","2020-Apr","Recruiting","Randomized","Double",2,"Healthy (Exposed)","None","Post Exposure Prophylaxis",NA,"HCQ",2000
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","Louisiana","2020-Apr","Recruiting","Randomized","Double",2,"Healthy (Exposed)","None","Post Exposure Prophylaxis",NA,"HCQ",2000
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","Maryland","2020-Apr","Recruiting","Randomized","Double",2,"Healthy (Exposed)","None","Post Exposure Prophylaxis",NA,"HCQ",2000
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","Massachusetts","2020-Apr","Recruiting","Randomized","Double",2,"Healthy (Exposed)","None","Post Exposure Prophylaxis",NA,"HCQ",2000
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","New York","2020-Apr","Recruiting","Randomized","Double",2,"Healthy (Exposed)","None","Post Exposure Prophylaxis",NA,"HCQ",2000
"NCT04328961","https://ClinicalTrials.gov/show/NCT04328961",NA,"United States","Washington","2020-Apr","Recruiting","Randomized","Double",2,"Healthy (Exposed)","None","Post Exposure Prophylaxis",NA,"HCQ",2000
"NCT04342156","https://ClinicalTrials.gov/show/NCT04342156",NA,"Singapore","Singapore","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Negative","Non-severe","Prophylaxis","Mortality, Hospitalization, Visits or Returns to Emergency Department, Invasive Mechanical Ventilation or ECMO","HCQ",1200
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Alabama","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","California","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Colorado","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Florida","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Georgia","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Illinois","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Louisiana","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Maryland","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Massachusetts","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Minnesota","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Missouri","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Nebraska","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","New York","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","North Carolina","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Pennsylvania","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Tennessee","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Texas","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Virginia","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United States","Washington","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Denmark","Copenhagen","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Germany","Nordrhein-Westfalen","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Germany","Berlin","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Macedonia","Skopje","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Greece","Athens","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Japan","Tokyo","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"South Korea","Gyeonggi","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"South Korea","Seoul","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Mexico","Mexico","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Singapore","Singapore","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"Spain","Barcelona","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","East Sussex","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","City","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","Leeds","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","London","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04280705","https://ClinicalTrials.gov/show/NCT04280705",NA,"United Kingdom","Newcastle Upon Tyne","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Remdesivir",572
"NCT04347915","https://ClinicalTrials.gov/show/NCT04347915",NA,"South Korea","Seoul","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe","Mixed",NA,"Clevudine, HCQ",60
"NCT04343755","https://ClinicalTrials.gov/show/NCT04343755",NA,"United States","New Jersey","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation","Plasma",55
"NCT04347889","https://ClinicalTrials.gov/show/NCT04347889",NA,"United States","New York","2020-Apr","Not Recruiting","Randomized","Single",2,"Negative","Non-severe","Healthcare Workers",NA,"HCQ",1212
"NCT04351620","https://ClinicalTrials.gov/show/NCT04351620",NA,"United States","Illinois","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Non-severe","Outpatients",NA,"HCQ",20
"NCT04315896","https://ClinicalTrials.gov/show/NCT04315896",NA,"Mexico","Mexico","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events","HCQ",500
"NCT04347980","https://ClinicalTrials.gov/show/NCT04347980",NA,"France","Paris","2020-Apr","Recruiting","Randomized","Single",2,"Yes","Severe","Hospitalized",NA,"Dexamethasone, HCQ",122
"NCT04318015","https://ClinicalTrials.gov/show/NCT04318015",NA,"Mexico","Mexico","2020-Mar","Recruiting","Randomized","Quadruple",2,"Healthy (Exposed)","None","Healthcare Workers","Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms","HCQ",400
"NCT04349631","https://ClinicalTrials.gov/show/NCT04349631",NA,"United States","Texas","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"No","Non-severe","Healthcare Workers",NA,"Stem Cells",56
"NCT04351191","https://ClinicalTrials.gov/show/NCT04351191",NA,"Pakistan","Punjab","2020-Apr","Not Recruiting","Randomized","Quadruple",4,"Yes","Non-severe","Outpatients",NA,"HCQ",400
"NCT04350450","https://ClinicalTrials.gov/show/NCT04350450",NA,"United States","New York","2020-Apr","Not Recruiting","Non-Randomized","Open-Label",2,"No","Non-severe","Healthcare Workers",NA,"HCQ",100
"NCT04334148","https://ClinicalTrials.gov/show/NCT04334148",NA,"United States","North Carolina","2020-Apr","Not Recruiting","Randomized","Triple",2,"Healthy","Non-severe","Healthcare Workers","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ",15000
"NCT04346589","https://ClinicalTrials.gov/show/NCT04346589",NA,"Italy","Rome","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Yes","Severe","Hospitalized",NA,"Plasma",10
"NCT04346589","https://ClinicalTrials.gov/show/NCT04346589",NA,"Italy","Bergamo","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Yes","Severe","Hospitalized",NA,"Plasma",10
"NCT04351295","https://ClinicalTrials.gov/show/NCT04351295",NA,"Egypt","Cairo","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Yes","Unspecified","Unspecified",NA,"FVP",40
"NCT04351347","https://ClinicalTrials.gov/show/NCT04351347",NA,"Egypt","Cairo","2020-Apr","Not Recruiting","Randomized","Open-Label",3,"Yes","Unspecified","Unspecified",NA,"HCQ, Invermectin, Nitazoxanide",60
"NCT04344535","https://ClinicalTrials.gov/show/NCT04344535",NA,"United States","New York","2020-Apr","Recruiting","Randomized","Quadruple",2,"Mixed","Mixed","Mixed","Clinical Improvement Score (Any), Distress","Plasma",500
"NCT04350281","https://ClinicalTrials.gov/show/NCT04350281",NA,"China","Hong Kong","2020-Apr","Recruiting","Randomized","Open-Label",2,"Yes","Severe","ICU Or Hospitalized",NA,"IFN, HCQ",80
"NCT04304053","https://ClinicalTrials.gov/show/NCT04304053",NA,"Spain","Barcelona","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe","Outpatients","Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Treatment-emergent Adverse Events, CD4, PaO2-FiO2, SpO2, Radiographic Findings","Darunavir/Cobicistat ,  HCQ",3040
"NCT04344457","https://ClinicalTrials.gov/show/NCT04344457",NA,"United States","Arizona","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Yes","Non-severe","Mixed","Clinical Improvement Score (Any), Cough, Fever, Treatment-emergent Adverse Events","HCQ, Indomethacin, azithromycin",80
"NCT04345653","https://ClinicalTrials.gov/show/NCT04345653",NA,"United States","New Jersey","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"No","Non-severe","Healthcare Workers","Viral Load or Clearance, Adverse Events, Serious Adverse Events","HCQ",45
"NCT04349592","https://ClinicalTrials.gov/show/NCT04349592",NA,"Qatar","Doha","2020-Apr","Not Recruiting","Randomized","Quadruple",3,"Yes","Non-severe","Mixed",NA,"HCQ, azithromycin",456
"NCT04342169","https://ClinicalTrials.gov/show/NCT04342169",NA,"United States","Utah","2020-Apr","Recruiting","Randomized","Open-Label",2,"Yes","Non-severe","Outpatients","ICU Admission, Depression, Anxiety","HCQ",400
"NCT04348461","https://ClinicalTrials.gov/show/NCT04348461",NA,"Spain","Madrid","2020-Apr","Not Recruiting","Randomized","Quadruple",2,"Yes","Severe","ICU",NA,"Stem Cells",100
"NCT04345991","https://ClinicalTrials.gov/show/NCT04345991",NA,"France","Paris","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mild","Mixed","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Ferritin, IL-6, D-Dimer, Creatinine Phosphokinase, Myoglobin, Troponin, Procalcitonin, Fibrinogen, Coagulation Test, Triglycerides, Electrolytes, Albumin, LDH, Urine Sample, PaO2-FiO2, SpO2, Respiratory Rate","Plasma",120
"NCT04252118","https://ClinicalTrials.gov/show/NCT04252118",NA,"China","Beijing","2020-Feb","Recruiting","Non-Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein, Creatinine Phosphokinase, ALT, CD4, CD8","Stem Cells",20
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Zaragoza","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Lymphocyte Count, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Madrid","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Lymphocyte Count, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma",278
"NCT04345523","https://ClinicalTrials.gov/show/NCT04345523",NA,"Spain","Asturias","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, MCP-1, Lymphocyte Count, Dendritic Cell Count, D-Dimer, Coagulation Test, ALT, Glucose, LDH","Plasma",278
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Rome","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Reggio Emilia","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Alessandria","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Cremona","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Cuneo","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Ferrara","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Firenze","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Genova","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Imperia","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","La Spezia","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Mantova","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Milano","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Novara","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Padova","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Parma","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Piacenza","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Pisa","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Bergamo","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Treviso","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Venezia","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04346355","https://ClinicalTrials.gov/show/NCT04346355",NA,"Italy","Verona","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, ECG","TCZ",398
"NCT04252664","https://ClinicalTrials.gov/show/NCT04252664",NA,"China","Hubei","2020-Feb","Suspended","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious Adverse Events, PaO2-FiO2, SpO2, Respiratory Rate","Remdesivir",308
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"United States","Missouri","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy (Exposed)","None","Healthcare Workers",NA,"HCQ",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"Australia","Victoria","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy (Exposed)","None","Healthcare Workers",NA,"HCQ",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"Canada","Ontario","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy (Exposed)","None","Healthcare Workers",NA,"HCQ",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"Ireland","Dublin","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy (Exposed)","None","Healthcare Workers",NA,"HCQ",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"South Africa","Pretoria","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy (Exposed)","None","Healthcare Workers",NA,"HCQ",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"South Africa","Gauteng","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy (Exposed)","None","Healthcare Workers",NA,"HCQ",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"South Africa","Western Cape","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy (Exposed)","None","Healthcare Workers",NA,"HCQ",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"United Kingdom","London","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy (Exposed)","None","Healthcare Workers",NA,"HCQ",55000
"NCT04333732","https://ClinicalTrials.gov/show/NCT04333732",NA,"Zambia","Lusaka","2020-Apr","Not Recruiting","Randomized","Double",4,"Healthy (Exposed)","None","Healthcare Workers",NA,"HCQ",55000
"NCT04324073","https://ClinicalTrials.gov/show/NCT04324073",NA,"France","Paris","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Sarilumab",239
"NCT04323527","https://ClinicalTrials.gov/show/NCT04323527",NA,"Brazil","Amazonas","2020-Mar","Recruiting","Randomized","Quadruple",2,"Mixed",NA,NA,"Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Treatment-emergent Adverse Events, Creatinine Phosphokinase, CK-MB, Troponin, AST","HCQ",440
"NCT04276688","https://ClinicalTrials.gov/show/NCT04276688",NA,"China","Hong Kong","2020-Feb","Completed","Randomized","Open-Label",3,"Confirmed",NA,"Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, IL-6, Tumor Necrosis Factor (Any)","Combination Antiviral",127
"NCT04345445","https://ClinicalTrials.gov/show/NCT04345445",NA,"Malaysia","Kuala Lumpur","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Moderate/severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation","TCZ",310
"NCT04333628","https://ClinicalTrials.gov/show/NCT04333628",NA,"Israel","Hazafon","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe","Outpatients","Clinical Improvement Score (Any), Viral Load or Clearance","HCQ",210
"NCT04344444","https://ClinicalTrials.gov/show/NCT04344444",NA,"United States","Louisiana","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Moderate/severe","Mixed",NA,"HCQ, Azt",600
"NCT04345692","https://ClinicalTrials.gov/show/NCT04345692",NA,"United States","Hawaii","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Heart Rate","HCQ",350
"NCT04273646","https://ClinicalTrials.gov/show/NCT04273646",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, C-Reactive Protein, Lymphocyte Count, Procalcitonin, CD4, CD8, PaO2-FiO2","Stem Cells",48
"NCT04341870","https://ClinicalTrials.gov/show/NCT04341870",NA,"France","Paris","2020-Apr","Recruiting","Randomized","Open-Label",3,"Confirmed","Moderate/severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ, AZT, Sarilumab",60
"NCT04344951","https://ClinicalTrials.gov/show/NCT04344951",NA,"Greece","Athens","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Unclear","Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, PaO2-FiO2","HCQ",60
"NCT04313127","https://ClinicalTrials.gov/show/NCT04313127",NA,"China","Hubei","2020-Mar","Not Recruiting","Non-Randomized","Open-Label",2,"Healthy","None","Healthy","Treatment-emergent Adverse Events, Serious Adverse Events, Antibodies","Vaccine",108
"NCT04344600","https://ClinicalTrials.gov/show/NCT04344600",NA,"United States","Maryland","2020-Apr","Not Recruiting","Randomized","Single",2,"Not Specified","Unspecified","Outpatients","Viral Load or Clearance","Interferon Therapy",164
"NCT04321616","https://ClinicalTrials.gov/show/NCT04321616",NA,"Norway","Oslo","2020-Mar","Recruiting","Randomized","Open-Label",3,"Confirmed","Severe","ICU Or Hospitalized","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Respiratory Rate","Remdesivir, HCQ",700
"NCT04343261","https://ClinicalTrials.gov/show/NCT04343261",NA,"United States","Connecticut","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU Or Hospitalized","Dyspnea, PaO2-FiO2, SpO2, Patient Positioning","Plasma Product",15
"NCT04340050","https://ClinicalTrials.gov/show/NCT04340050",NA,"United States","Illinois","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU Or Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO","Plasma Product",10
"NCT04342650","https://ClinicalTrials.gov/show/NCT04342650",NA,"Brazil","Amazonas","2020-Apr","Recruiting","Randomized","Quadruple",2,"Suspected","Mixed","Mixed","Adverse Events, Natural Killer Cell Count","HCQ",210
"NCT04345419","https://ClinicalTrials.gov/show/NCT04345419",NA,"Egypt","Cairo","2020-Apr","Not Recruiting","Randomized","Single",5,"Confirmed","Unspecified","Unclear","Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events","HCQ, FVP, Nitazoxanide, Ivermectin, Niclosamide",100
"NCT04345289","https://ClinicalTrials.gov/show/NCT04345289",NA,"Denmark","Copenhagen","2020-Apr","Not Recruiting","Randomized","Quadruple",6,"Confirmed","Mixed","Unclear","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Plasma, sarilumab, HCQ, Baricitinib",1500
"NCT04299152","https://ClinicalTrials.gov/show/NCT04299152",NA,"China","Beijing","2020-Mar","Not Recruiting","Randomized","Single",2,"Confirmed",NA,NA,"Viral Load or Clearance, Other Mild Symptoms, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Natural Killer Cell Count, Radiographic Findings","Stem Cell",20
"NCT04334512","https://ClinicalTrials.gov/show/NCT04334512",NA,"United States","California","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Low Risk","Viral Load or Clearance, Radiographic Findings","HCQ, vitamins, AZT",600
"NCT04329923","https://ClinicalTrials.gov/show/NCT04329923",NA,"United States","Pennsylvania","2020-Apr","Recruiting","Randomized","Triple",4,"Confirmed And Healthy","Mixed","Mixed","Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Dyspnea","HCQ",400
"NCT04331470","https://ClinicalTrials.gov/show/NCT04331470",NA,"Iran","Fars","2020-Apr","Recruiting","Randomized","Double",2,"Confirmed",NA,NA,"Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2, SpO2","Levamisole, LPV/r, HCQ",30
"NCT04336332","https://ClinicalTrials.gov/show/NCT04336332",NA,"United States","New Jersey","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe","Mixed","Mortality, Platelet Count","HCQ, azithromycin",160
"NCT04291729","https://ClinicalTrials.gov/show/NCT04291729",NA,"China","Jiangxi","2020-Mar","Completed","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospitalized","Hospitalization, Visits or Returns to Emergency Department, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Combination Antiviral",11
"NCT04339816","https://ClinicalTrials.gov/show/NCT04339816",NA,"Czechia","Prague","2020-Apr","Not Recruiting","Randomized","Triple",3,"Confirmed","Severe","ICU","Mortality, Viral Load or Clearance, Treatment-emergent Adverse Events","AZT, HCQ",240
"NCT04261517","https://ClinicalTrials.gov/show/NCT04261517","http://www.zjujournals.com/med/EN/10.3785/j.issn.1008-9292.2020.03.03#1","China","Shanghai","2020-Feb","Completed w. Results","Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality","HCQ",30
"NCT04330495","https://ClinicalTrials.gov/show/NCT04330495",NA,"Spain","Madrid","2020-Apr","Not Recruiting","Randomized","Double",2,"Confirmed",NA,NA,"Mortality, ICU Admission","HCQ",800
"NCT04315480","https://ClinicalTrials.gov/show/NCT04315480",NA,"Italy","Ancona","2020-Mar","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, D-Dimer, Antibodies, PaO2-FiO2, SpO2","TCZ",38
"NCT04322123","https://ClinicalTrials.gov/show/NCT04322123",NA,"Brazil","Brasilia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected",NA,"Mixed","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Lymphocyte Count, D-Dimer, Antibodies, PaO2-FiO2, SpO2","HCQ ,  Azithromycin",630
"NCT04322123","https://ClinicalTrials.gov/show/NCT04322123",NA,"Brazil","Distrito Federal","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected",NA,"Mixed","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Lymphocyte Count, D-Dimer, Antibodies, PaO2-FiO2, SpO2","HCQ ,  Azithromycin",630
"NCT04322123","https://ClinicalTrials.gov/show/NCT04322123",NA,"Brazil","Rio De Janeiro","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected",NA,"Mixed","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Lymphocyte Count, D-Dimer, Antibodies, PaO2-FiO2, SpO2","HCQ ,  Azithromycin",630
"NCT04322396","https://ClinicalTrials.gov/show/NCT04322396",NA,"Denmark","Copenhagen","2020-Mar","Recruiting","Randomized","Quadruple",3,"Confirmed",NA,"Hospitalized","Clinical Improvement Score (Any)","Azithromycin ,  HCQ",226
"NCT04283461","https://ClinicalTrials.gov/show/NCT04283461",NA,"United States","Georgia","2020-Feb","Recruiting","Non-Randomized","Open-Label",2,"Healthy","None","Healthy","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, Ferritin, IL-6, D-Dimer, Glucose, Antibodies, PaO2-FiO2, SpO2","Vaccine",45
"NCT04283461","https://ClinicalTrials.gov/show/NCT04283461",NA,"United States","Maryland","2020-Feb","Recruiting","Non-Randomized","Open-Label",2,"Healthy","None","Healthy","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, Ferritin, IL-6, D-Dimer, Glucose, Antibodies, PaO2-FiO2, SpO2","Vaccine",45
"NCT04283461","https://ClinicalTrials.gov/show/NCT04283461",NA,"United States","Washington","2020-Feb","Recruiting","Non-Randomized","Open-Label",2,"Healthy","None","Healthy","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Anti SARS-COV-2 Titers, Ferritin, IL-6, D-Dimer, Glucose, Antibodies, PaO2-FiO2, SpO2","Vaccine",45
"CHICTR2000031888","http://www.chictr.org.cn/showproj.aspx?proj=52106",NA,"China","Guangdong","2020-Apr","Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed","Unclear","Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, C-Reactive Protein, White Blood Cell Count, CD4, CD8, Renal Outcome (Unspecified)","Traditional Chinese Medicine",300
"CHICTR2000030750","http://www.chictr.org.cn/showproj.aspx?proj=50928",NA,"China","Guangdong","2020-Mar","Not Recruiting","Randomized","Unspecified",4,"Confirmed","Non-severe",NA,"Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever","Vaccine",120
"NCT04333225","https://ClinicalTrials.gov/show/NCT04333225",NA,"United States","Texas","2020-Apr","Recruiting","Non-Randomized","Open-Label",2,"Exposed","None","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), SpO2, Radiographic Findings","HCQ",360
"NCT04303299","https://ClinicalTrials.gov/show/NCT04303299",NA,"Thailand","Nan","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Outpatients","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Darunavir, Oseltamivir, FVP, HCQ",320
"NCT04338698","https://ClinicalTrials.gov/show/NCT04338698",NA,"Pakistan","Islamabad","2020-Apr","Not Recruiting","Randomized","Double",3,"Confirmed","Mixed","Mixed","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","HCQ, oseltamivir, AZT",500
"NCT04310228","https://ClinicalTrials.gov/show/NCT04310228",NA,"China","Beijing","2020-Mar","Recruiting","Randomized","Open-Label",3,"Confirmed",NA,NA,"Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Favipiravir ,  TCZ",150
"NCT04310228","https://ClinicalTrials.gov/show/NCT04310228",NA,"China","Hubei","2020-Mar","Recruiting","Randomized","Open-Label",3,"Confirmed",NA,NA,"Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Favipiravir ,  TCZ",150
"NCT04341610","https://ClinicalTrials.gov/show/NCT04341610",NA,"Denmark","Copenhagen","2020-Apr","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","ICU","Mortality, C-Reactive Protein, White Blood Cell Count, eGFR, CD4, CD8","Stem cell",40
"NCT04341727","https://ClinicalTrials.gov/show/NCT04341727",NA,"United States","Missouri","2020-Apr","Recruiting","Randomized","Open-Label",3,"Confirmed","Mixed","Hospitalized",NA,"HCQ, AZT",500
"NCT04302766","https://ClinicalTrials.gov/show/NCT04302766",NA,"United States","Virginia","2020-Mar","Recruiting","Unspecified","Unspecified",NA,"Confirmed","Mixed","Us Military",NA,"Remdesivir",NA
"NCT04328467","https://ClinicalTrials.gov/show/NCT04328467",NA,"United States","Minnesota","2020-Mar","Recruiting","Randomized","Quadruple",2,"Healthy (Exposed)",NA,"Healthcare Workers",NA,"HCQ",3500
"NCT04339660","https://ClinicalTrials.gov/show/NCT04339660",NA,"China","Hubei","2020-Apr","Recruiting","Randomized","Triple",2,"Confirmed","Mixed","Hospitalized","Mortality, Viral Load or Clearance, Secondary CoViD-19 Re-infection","Stem cell",30
"NCT04329832","https://ClinicalTrials.gov/show/NCT04329832",NA,"United States","Utah","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed And Suspected",NA,"Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, Azithromycin",300
"NCT04340544","https://ClinicalTrials.gov/show/NCT04340544",NA,"Germany","Berlin","2020-Apr","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Mild","Outpatients","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ",2700
"NCT04334382","https://ClinicalTrials.gov/show/NCT04334382",NA,"United States","Utah","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe","Outpatients","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ",1550
"NCT04340349","https://ClinicalTrials.gov/show/NCT04340349",NA,"Mexico","Mexico","2020-Apr","Not Recruiting","Randomized","Triple",2,"Negative","Non-severe","Prophylaxis","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","HCQ, Bromhexine",100
"NCT04336904","https://ClinicalTrials.gov/show/NCT04336904",NA,"Italy","Milano","2020-Apr","Not Recruiting","Randomized","Double",2,"Confirmed","Mixed","Mixed","Mortality, ICU Admission","FVP",100
"NCT04328012","https://ClinicalTrials.gov/show/NCT04328012",NA,"United States","New York","2020-Mar","Recruiting","Randomized","Quadruple",4,"Confirmed",NA,"Hospitalized","Clinical Improvement Score (Any), C-Reactive Protein, Lymphocyte Count, D-Dimer","LPV/r, HCQ, losartan",4000
"NCT04323800","https://ClinicalTrials.gov/show/NCT04323800",NA,"United States","Maryland","2020-Mar","Not Recruiting","Randomized","Triple",2,"Healthy (Exposed)","None","Healthy (Exposed)","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, SpO2","Plasma Product",150
"NCT04338906","https://ClinicalTrials.gov/show/NCT04338906",NA,"Germany","Berlin","2020-Apr","Not Recruiting","Randomized","Quadruple",3,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), C-Reactive Protein, Troponin","Camostat mesilate, HCQ",334
"NCT04325893","https://ClinicalTrials.gov/show/NCT04325893",NA,"France","Paris","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed",NA,NA,"Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, CK-MB, Procalcitonin, SpO2, Radiographic Findings","HCQ/placebo",1300
"NCT04325893","https://ClinicalTrials.gov/show/NCT04325893",NA,"France","Cher","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed",NA,NA,"Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, CK-MB, Procalcitonin, SpO2, Radiographic Findings","HCQ/placebo",1300
"NCT04325893","https://ClinicalTrials.gov/show/NCT04325893",NA,"Monaco","Monaco","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed",NA,NA,"Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, Lymphocyte Count, CK-MB, Procalcitonin, SpO2, Radiographic Findings","HCQ/placebo",1300
"NCT04331808","https://ClinicalTrials.gov/show/NCT04331808",NA,"China","Beijing","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized","Mortality, ICU Admission, PaO2-FiO2, Radiographic Findings, Blood pH","TCZ",240
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"United States","Minnesota","2020-Mar","Recruiting","Randomized","Quadruple",2,"Mixed","Mixed","Post Exposure Prophylaxis","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ",3000
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"United States","New York","2020-Mar","Recruiting","Randomized","Quadruple",2,"Mixed","Mixed","Post Exposure Prophylaxis","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ",3000
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"Canada","Alberta","2020-Mar","Recruiting","Randomized","Quadruple",2,"Mixed","Mixed","Post Exposure Prophylaxis","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ",3000
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"Canada","Manitoba","2020-Mar","Recruiting","Randomized","Quadruple",2,"Mixed","Mixed","Post Exposure Prophylaxis","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ",3000
"NCT04308668","https://ClinicalTrials.gov/show/NCT04308668",NA,"Canada","Quebec","2020-Mar","Recruiting","Randomized","Quadruple",2,"Mixed","Mixed","Post Exposure Prophylaxis","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2, Blood pH","HCQ",3000
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Alessandria","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Rome","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Catania","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Cosenza","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Modena","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Ravenna","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Reggio Calabria","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Rimini","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Varese","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"TCZ",400
"NCT04317092","https://ClinicalTrials.gov/show/NCT04317092",NA,"Italy","Verona","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"TCZ",400
"NCT04331834","https://ClinicalTrials.gov/show/NCT04331834",NA,"Spain","Barcelona","2020-Apr","Recruiting","Randomized","Quadruple",2,"Negative","None","Healthcare Workers","Viral Load or Clearance, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ",440
"NCT04336254","https://ClinicalTrials.gov/show/NCT04336254",NA,"China","Hubei","2020-Apr","Recruiting","Randomized","Triple",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Treatment-emergent Adverse Events, C-Reactive Protein, SpO2, Respiratory Rate, Radiographic Findings","Stem cells",20
"NCT04332094","https://ClinicalTrials.gov/show/NCT04332094",NA,"Spain","Barcelona","2020-Apr","Recruiting","Randomized","Open-Label",3,"Confirmed","Non-severe",NA,"Mortality, Invasive Mechanical Ventilation or ECMO","HCQ , TCZ, azithromycin",276
"NCT04288102","https://ClinicalTrials.gov/show/NCT04288102",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, CD4, PaO2-FiO2, SpO2, Radiographic Findings","Stem Cells",90
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Australia","Victoria","2020-Mar","Recruiting","Randomized","Open-Label",2,"Healthy (Exposed)",NA,"Healthcare Workers",NA,"BCG Vaccine",4170
"NCT04327206","https://ClinicalTrials.gov/show/NCT04327206",NA,"Australia","Western Australia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Healthy (Exposed)",NA,"Healthcare Workers",NA,"BCG Vaccine",4170
"NCT04336748","https://ClinicalTrials.gov/show/NCT04336748",NA,"Austria","Vienna","2020-Apr","Not Recruiting","Randomized","Triple",2,"Healthy","Non-severe","Healthcare Workers","Viral Load or Clearance, Labor Absenteeism","HCQ",440
"NCT04322773","https://ClinicalTrials.gov/show/NCT04322773",NA,"Denmark","Copenhagen","2020-Mar","Recruiting","Randomized","Open-Label",4,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein","TCZ",200
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","California","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Colorado","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Connecticut","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","District Of Columbia","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Florida","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Georgia","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Illinois","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Louisiana","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Maryland","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Massachusetts","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Michigan","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Minnesota","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","New Jersey","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","New York","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Oklahoma","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Oregon","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Pennsylvania","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Texas","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Utah","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Virginia","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04315298","https://ClinicalTrials.gov/show/NCT04315298",NA,"United States","Washington","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",400
"NCT04334967","https://ClinicalTrials.gov/show/NCT04334967",NA,"United States","Oregon","2020-Apr","Recruiting","Randomized","Single",2,"Confirmed","Non-severe","Outpatients","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","HCQ",1250
"NCT04333251","https://ClinicalTrials.gov/show/NCT04333251",NA,"United States","Texas","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized","Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Plasma product",115
"NCT04333355","https://ClinicalTrials.gov/show/NCT04333355",NA,"Mexico","Nuevo Leon","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Viral Load or Clearance, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Plasma Product",20
"NCT04328441","https://ClinicalTrials.gov/show/NCT04328441",NA,"Netherlands","Amsterdam","2020-Mar","Recruiting","Randomized","Quadruple",2,"Healthy",NA,"Healthcare Workers",NA,"BCG Vaccine",1500
"NCT04328441","https://ClinicalTrials.gov/show/NCT04328441",NA,"Netherlands","Gelderland","2020-Mar","Recruiting","Randomized","Quadruple",2,"Healthy",NA,"Healthcare Workers",NA,"BCG Vaccine",1500
"NCT04328441","https://ClinicalTrials.gov/show/NCT04328441",NA,"Netherlands","Zuid-Holland","2020-Mar","Recruiting","Randomized","Quadruple",2,"Healthy",NA,"Healthcare Workers",NA,"BCG Vaccine",1500
"NCT04328441","https://ClinicalTrials.gov/show/NCT04328441",NA,"Netherlands","Utrecht","2020-Mar","Recruiting","Randomized","Quadruple",2,"Healthy",NA,"Healthcare Workers",NA,"BCG Vaccine",1500
"NCT04333368","https://ClinicalTrials.gov/show/NCT04333368",NA,"France","Paris","2020-Apr","Not Recruiting","Randomized","Triple",2,"Confirmed","Severe","ICU","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Antibodies, PaO2-FiO2, Quality of Life","Stem cells",60
"NCT04332835","https://ClinicalTrials.gov/show/NCT04332835",NA,"Colombia","Cundinamarca","2020-Apr","Not Recruiting","Randomized","Open-Label",3,"Confirmed","Mixed","Hospitalized","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, IgG, IgM or IgA","Azithromycin ,  HCQ",80
"NCT04316377","https://ClinicalTrials.gov/show/NCT04316377",NA,"Norway","Oslo","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance","HCQ",202
"NCT04328272","https://ClinicalTrials.gov/show/NCT04328272",NA,"Pakistan","Islamabad","2020-Mar","Not Recruiting","Randomized","Single",3,"Confirmed","Mixed","Hospitalized","Clinical Improvement Score (Any), C-Reactive Protein, Lymphocyte Count, D-Dimer","HCQ, Azithromycin",75
"NCT04331899","https://ClinicalTrials.gov/show/NCT04331899",NA,"United States","California","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Non-severe","Outpatients","Viral Load or Clearance","Interferon Therapy",120
"NCT04331600","https://ClinicalTrials.gov/show/NCT04331600",NA,"Poland","Lower Silesian","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Outpatients","Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Serious or Seconday Infections","HCQ",400
"NCT04331613","https://ClinicalTrials.gov/show/NCT04331613",NA,"China","Beijing","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","Mortality, Viral Load or Clearance, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-6, IL-8, Lymphocyte Count, CK-MB, Procalcitonin, SpO2","Stem cells",9
"NCT04332380","https://ClinicalTrials.gov/show/NCT04332380",NA,"Colombia","Cundinamarca","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, IgG, IgM or IgA","Plasma Product",10
"CHICTR2000031494","http://www.chictr.org.cn/showproj.aspx?proj=51904",NA,"China","Hubei","2020-Apr","Recruiting","Single-Arm","Unspecified",2,"Confirmed","Severe","Hospitalized","Radiographic Findings","Stem cells",36
"NCT04330586","https://ClinicalTrials.gov/show/NCT04330586",NA,"South Korea","Seoul","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Non-severe","Outpatients","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Ciclesonide ,  HCQ",141
"NCT04330144","https://ClinicalTrials.gov/show/NCT04330144",NA,"South Korea","Seoul","2020-Apr","Not Recruiting","Randomized","Single",2,"Healthy (Exposed)",NA,NA,"Viral Load or Clearance","HCQ",2486
"NCT04320238","https://ClinicalTrials.gov/show/NCT04320238",NA,"China","Hubei","2020-Mar","Recruiting","Non-Randomized","Open-Label",2,"Healthy (Exposed)","None","Healthcare Workers","Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, Treatment-emergent Adverse Events","Interferon Therapy",2944
"NCT04327349","https://ClinicalTrials.gov/show/NCT04327349",NA,"Iran","Mazandaran","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,NA,"Mortality, Hospitalization, Non-invasive Ventilation, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Creatinine Phosphokinase, CK-MB, ALT, AST, LDH, IgG, IgM or IgA, CD4, CD8, PaO2-FiO2","Plasma",30
"CHICTR2000031430","http://www.chictr.org.cn/showproj.aspx?proj=49254",NA,"China","Beijing","2020-Mar","Recruiting","Non-Randomized","Unspecified",2,"Confirmed","Mixed","Hospitalized","C-Reactive Protein, IL-6, Interferon (Any), Lymphocyte Count, D-Dimer, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Coagulation Test, ALT, AST, Albumin, Bilirubin, LDH, IgG, IgM or IgA, Blood Gas, ECG, 6-Minute Walking Distance, Radiographic Findings, Quality of Life","Stem cells",200
"NCT04303507","https://ClinicalTrials.gov/show/NCT04303507",NA,"United Kingdom","Oxford","2020-Mar","Not Recruiting","Randomized","Double",2,"Healthy (Exposed)","None","Healthcare Workers","Viral Load or Clearance, Pneumonia or ARDS","HCQ",40000
"CHICTR2000031319","http://www.chictr.org.cn/showproj.aspx?proj=51647",NA,"China","Hubei","2020-Mar","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Severe",NA,"Viral Load or Clearance, Fever, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Neutrophils, Creatinine Phosphokinase, CK-MB, Troponin, Procalcitonin, ALT, AST, LDH, CD4, CD8, SpO2, Respiratory Rate, Radiographic Findings","Stem cells",20
"NCT04323631","https://ClinicalTrials.gov/show/NCT04323631",NA,"Israel","Haifa","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Mixed","Mortality, Serious or Seconday Infections","HCQ",1116
"CHICTR2000030704","http://www.chictr.org.cn/showproj.aspx?proj=50778",NA,"China","Jiangsu","2020-Mar","Status Unclear","Randomized","Unspecified",2,"Confirmed",NA,NA,"Non-invasive Ventilation, White Blood Cell Count, Creatinine Phosphokinase, CK-MB, ALT, AST, PaO2-FiO2, Respiratory Rate","Traditional Chinese Medicine",50
"NCT04321421","https://ClinicalTrials.gov/show/NCT04321421",NA,"Italy","Pavia","2020-Mar","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Antibodies","Plasma Product",49
"NCT04318444","https://ClinicalTrials.gov/show/NCT04318444",NA,"United States","New York","2020-Mar","Not Recruiting","Randomized","Quadruple",2,"Healthy (Exposed)","None","Healthy (Exposed)","Viral Load or Clearance","HCQ",1600
"NCT04315948","https://ClinicalTrials.gov/show/NCT04315948",NA,"France","Paris","2020-Mar","Recruiting","Randomized","Open-Label",5,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, White Blood Cell Count, Platelet Count, Creatinine Phosphokinase, CK-MB, Prothrombin, Electrolytes, INR, ALT, AST, Bilirubin, Glucose","Remdesivir, LPV/r, Interferon, HCQ",3100
"NCT04319900","https://ClinicalTrials.gov/show/NCT04319900",NA,"China","Beijing","2020-Mar","Recruiting","Randomized","Double",3,"Confirmed",NA,NA,"Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious or Seconday Infections, C-Reactive Protein, Lymphocyte Count, Radiographic Findings","FVP, HCQ",150
"CHICTR2000031204","http://www.chictr.org.cn/showproj.aspx?proj=49420",NA,"China","Beijing","2020-Mar","Recruiting","Randomized","Single",2,"Confirmed",NA,NA,"Viral Load or Clearance, Fever, Serious or Seconday Infections, C-Reactive Protein, Lymphocyte Count, Radiographic Findings","HCQ",300
"NCT04273763","https://ClinicalTrials.gov/show/NCT04273763",NA,"China","Zhejiang","2020-Feb","Recruiting","Randomized","Open-Label",3,"Confirmed Or Suspected","Non-severe","Outpatients","Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, PaO2-FiO2, SpO2, Respiratory Rate","Combination Antiviral",60
"CHICTR2000031196","http://www.chictr.org.cn/showproj.aspx?proj=51112",NA,"China","Beijing","2020-Mar","Recruiting","Non-Randomized","Unspecified",2,"Confirmed",NA,NA,"Viral Load or Clearance, Adverse Events","Lopinavir/ritonvair",90
"CHICTR2000029868","http://www.chictr.org.cn/showproj.aspx?proj=49524",NA,"China","Shanghai","2020-Feb","Completed","Randomized","Open-Label",2,"Confirmed","Mixed",NA,"Viral Load or Clearance, Adverse Events","HCQ",360
"CHICTR2000029496","http://www.chictr.org.cn/showproj.aspx?proj=48809",NA,"China","Hunan","2020-Feb","Recruiting","Randomized","Open-Label",3,"Confirmed",NA,"Hospitalized","Viral Load or Clearance, Adverse Events","Cyotkine protein injection",90
"CHICTR2000030987","http://www.chictr.org.cn/showproj.aspx?proj=51329",NA,"China","Beijing","2020-Mar","Recruiting","Randomized","Unspecified",3,"Resolved",NA,"Discharged","Viral Load or Clearance, Pneumonia or ARDS, Cough, Dyspnea","HCQ , /- Favipiravir",150
"NCT04276896","https://ClinicalTrials.gov/show/NCT04276896",NA,"China","Guangdong","2020-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Radiographic Findings","Vaccine",100
"CHICTR2000030944","http://www.chictr.org.cn/showproj.aspx?proj=50199",NA,"China","Jiangxi","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Severe",NA,"Mortality, Treatment-emergent Adverse Events","Stem cells",20
"NCT04313322","https://ClinicalTrials.gov/show/NCT04313322",NA,"Jordan","Amman","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,NA,"Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings","Stem Cells",5
"CHICTR2000030929","http://www.chictr.org.cn/showproj.aspx?proj=50696",NA,"China","Hubei","2020-Mar","Not Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Clinical Improvement Score (Any), Cough, Fever, Other Mild Symptoms","Plasma",60
"NCT04255017","https://ClinicalTrials.gov/show/NCT04255017",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Single",3,"Confirmed",NA,NA,"Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate, CK-MB, ALT, PaO2-FiO2, SpO2, Radiographic Findings","Combination Antiviral",400
"NCT04254874","https://ClinicalTrials.gov/show/NCT04254874",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Single",2,"Confirmed","Mixed",NA,"Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate, CK-MB, ALT, PaO2-FiO2, SpO2, Radiographic Findings","Combination Antiviral",100
"NCT04264858","https://ClinicalTrials.gov/show/NCT04264858",NA,"China","Hubei","2020-Feb","Not Recruiting","Non-Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Antibodies, PaO2-FiO2, Radiographic Findings","Plasma",10
"CHICTR2000030166","http://www.chictr.org.cn/showproj.aspx?proj=49696",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed",NA,"Viral Load or Clearance, Fever, 3CL Mpro, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Natural Killer Cell Count, Dendritic Cell Count, Neutrophils, Platelet Count, Creatinine Phosphokinase, CK-MB, ALT, AST, Urine Sample, Stool Sample, Radiographic Findings","Interferon Therapy",20
"CHICTR2000030922","http://www.chictr.org.cn/showproj.aspx?proj=51141",NA,"China","Guangdong","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe","Outpatients","Mortality, Viral Load or Clearance, Pneumonia or ARDS, ALT, AST","Interferon, ribavirin, arbidol, ribavirin",30
"CHICTR2000030894","http://www.chictr.org.cn/showproj.aspx?proj=51126",NA,"China","Beijing","2020-Mar","Recruiting","Randomized","Unspecified",3,"Confirmed",NA,NA,"Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein, Lymphocyte Count, Radiographic Findings","Favipiravir",150
"CHICTR2000030841","http://www.chictr.org.cn/showproj.aspx?proj=51072",NA,"China","Hubei","2020-Mar","Recruiting","Non-Randomized","Unspecified",2,"Confirmed","Severe",NA,"Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings","Plasma product",10
"CHICTR2000030187","http://www.chictr.org.cn/showproj.aspx?proj=50057",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Procalcitonin, ALT, AST, Albumin, Bilirubin","LPV/r",60
"CHICTR2000030835","http://www.chictr.org.cn/showproj.aspx?proj=51050",NA,"China","Henan","2020-Mar","Recruiting","Single-Arm","Open-Label",2,"Confirmed","Severe","Hospitalized","C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-17, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Natural Killer Cell Count, Procalcitonin, ALT, AST, Albumin, Bilirubin, Glucose, Urine Sample, Radiographic Findings, Depression, Anxiety, Distress","Stem cells",20
"CHICTR2000030580","http://www.chictr.org.cn/showproj.aspx?proj=50693",NA,"China","Shanghai","2020-Mar","Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","Hospitalized","Viral Load or Clearance, IL-6, IL-10, Tumor Necrosis Factor (Any), Radiographic Findings","TCZ ,  Adalimumab",60
"NCT04307693","https://ClinicalTrials.gov/show/NCT04307693",NA,"South Korea","Seoul","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe","Outpatients","Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Other Mild Symptoms, Adverse Events, SpO2, Respiratory Rate","LPV/r",150
"CHICTR2000030718","http://www.chictr.org.cn/showproj.aspx?proj=50843",NA,"China","Hubei","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Serious Adverse Events, Granulocyte Stimulaiting Factor, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Natural Killer Cell Count, Neutrophils, Platelet Count, ALT, AST, Albumin, Bilirubin, IgG, IgM or IgA, Blood Gas","HCQ",80
"NCT04302519","https://ClinicalTrials.gov/show/NCT04302519",NA,"China","Beijing","2020-Mar","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","PaO2-FiO2, SpO2, Radiographic Findings, Hypoxia, Hypoxemia","Stem Cells",24
"CHICTR2000030702","http://www.chictr.org.cn/showproj.aspx?proj=50537",NA,"China","Beijing","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Convalescent plasma",50
"NCT04299724","https://ClinicalTrials.gov/show/NCT04299724",NA,"China","Guangdong","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed And Healthy",NA,NA,"Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein, Lymphocyte Count","Vaccine",100
"CHICTR2000029308","http://www.chictr.org.cn/showproj.aspx?proj=48684","https://www.nejm.org/doi/pdf/10.1056/NEJMoa2001282?articleTools=true","China","Hubei","2020-Jan","Completed w. Results","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","LPV/r",160
"CHICTR2000029580","http://www.chictr.org.cn/showproj.aspx?proj=49088",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Single",2,"Confirmed","Severe",NA,"Adverse Events","Stem Cell, Ruxolitinib",70
"CHICTR2000029638","http://www.chictr.org.cn/showproj.aspx?proj=49224",NA,"China","Sichuan","2020-Feb","Recruiting","Randomized","Single",2,"Confirmed","Mixed",NA,"Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-17, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, White Blood Cell Count, Hemoglobin, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, Myoglobin, Troponin, Procalcitonin, Coagulation Test, Urine Sample, Blood Gas, Blood Pressure, Heart Rate, SpO2, Respiratory Rate, Radiographic Findings","Interferon Therapy",100
"CHICTR2000029757","http://www.chictr.org.cn/showproj.aspx?proj=49081",NA,"China","Beijing","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Plasma Product",200
"CHICTR2000029993","http://www.chictr.org.cn/showproj.aspx?proj=49435",NA,"China","Guangdong","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed",NA,"Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Serious or Seconday Infections, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Traditional Chinese Medicine",40
"CHICTR2000030627","http://www.chictr.org.cn/showproj.aspx?proj=50727",NA,"China","Henan","2020-Mar","Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Viral Load or Clearance, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Plasma Product",30
"CHICTR2000030535","http://www.chictr.org.cn/showproj.aspx?proj=49790",NA,"China","Sichuan","2020-Mar","Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed",NA,"Mortality, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Radiographic Findings","Ebastine",100
"NCT04295551","https://ClinicalTrials.gov/show/NCT04295551",NA,"China","Beijing","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed",NA,"Cough, Fever, Dyspnea","Ritonavir/Lopinavir, Tcm",80
"CHICTR2000030487","http://www.chictr.org.cn/showproj.aspx?proj=50507",NA,"China","Henan","2020-Mar","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Mixed",NA,"Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, CD4, CD8","Azvudine",10
"NCT04293887","https://ClinicalTrials.gov/show/NCT04293887",NA,"China","Hebei","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized","ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, SpO2, Respiratory Rate","Interferon Therapy",328
"CHICTR2000030484","http://www.chictr.org.cn/showproj.aspx?proj=50263",NA,"China","Hubei","2020-Mar","Not Recruiting","Randomized","Unspecified",3,"Confirmed",NA,NA,"Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea, Serious Adverse Events, C-Reactive Protein, PaO2-FiO2, Radiographic Findings","Stem Cells",90
"CHICTR2000030480","http://www.chictr.org.cn/showproj.aspx?proj=50470",NA,"China","Hubei","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Treatment-emergent Adverse Events","Interferon Therapy",328
"CHICTR2000029898","http://www.chictr.org.cn/showproj.aspx?proj=49482",NA,"China","Beijing","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, IgG, IgM or IgA","HCQ",100
"CHICTR2000029975","http://www.chictr.org.cn/showproj.aspx?proj=49592",NA,"China","Jilin","2020-Feb","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,NA,"Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, SpO2","HCQ",10
"CHICTR2000030424","http://www.chictr.org.cn/showproj.aspx?proj=50174",NA,"China","Henan","2020-Mar","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Mixed",NA,"Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, CD4, CD8","Azivudine",30
"CHICTR2000030013","http://www.chictr.org.cn/showproj.aspx?proj=49796",NA,"China","Beijing","2020-Feb","Not Recruiting","Non-Randomized","Unspecified",2,"Healthy (Exposed)","None","Healthcare Workers","Pneumonia or ARDS, Cough, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, SpO2, Radiographic Findings","Interferon Therapy",450
"CHICTR2000029899","http://www.chictr.org.cn/showproj.aspx?proj=49536",NA,"China","Beijing","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe","Outpatients","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IgG, IgM or IgA","HCQ",100
"NCT04286503","https://ClinicalTrials.gov/show/NCT04286503",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Open-Label",3,"Confirmed","Mixed","Mixed","Viral Load or Clearance, Fever, Radiographic Findings","Carrimycin, Arbidol, HCQ, LPV/r",520
"CHICTR2000029759","http://www.chictr.org.cn/showproj.aspx?proj=49352",NA,"China","Chongqing","2020-Feb","Status Unclear","Randomized","Open-Label",3,"Confirmed","Mixed","Hospitalized","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea","Ritonavir/Lopinavir, Arbidol, Asc09",60
"CHICTR2000030218","http://www.chictr.org.cn/showproj.aspx?proj=50115",NA,"China","Jiangxi","2020-Feb","Recruiting","Randomized","Unspecified",3,"Confirmed","Non-severe",NA,"Viral Load or Clearance, Pneumonia or ARDS","Traditional Chinese Medicine",80
"NCT04276987","https://ClinicalTrials.gov/show/NCT04276987",NA,"China","Beijing","2020-Feb","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, IL-1, IL-2, IL-6, IL-8, Lymphocyte Count, D-Dimer, LDH, Radiographic Findings","Stem Cells",30
"CHICTR2000030196","http://www.chictr.org.cn/showproj.aspx?proj=49883",NA,"China","Hubei","2020-Feb","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed",NA,"Adverse Events, Serious Adverse Events, IL-1, IL-6, Tumor Necrosis Factor (Any), Interferon (Any)","TCZ",60
"CHICTR2000030138","http://www.chictr.org.cn/showproj.aspx?proj=50004",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Double",2,"Confirmed Or Suspected","Severe",NA,"Clinical Improvement Score (Any)","Stem Cells",60
"CHICTR2000030020","http://www.chictr.org.cn/showproj.aspx?proj=49812",NA,"China","Hunan","2020-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Suspected",NA,NA,"Viral Load or Clearance, Lymphocyte Count, Radiographic Findings","Stem Cells",20
"CHICTR2000030113","http://www.chictr.org.cn/showproj.aspx?proj=49988",NA,"China","Guangdong","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"Blood Gas, Radiographic Findings, Renal Outcome (Unspecified)","Favipiravir",30
"CHICTR2000030179","http://www.chictr.org.cn/showproj.aspx?proj=50059",NA,"China","Jiangxi","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Viral Load or Clearance","Plasma Product",100
"CHICTR2000030173","http://www.chictr.org.cn/showproj.aspx?proj=49229",NA,"China","Hunan","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"Viral Load or Clearance, Radiographic Findings","Stem Cells",60
"CHICTR2000029803","http://www.chictr.org.cn/showproj.aspx?proj=49428",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Open-Label",4,"Healthy (Exposed)",NA,"Healthy (Exposed)","Viral Load or Clearance, Cough, Fever, Serious Adverse Events, C-Reactive Protein, SpO2, Radiographic Findings","HCQ, Arbidol",320
"CHICTR2000029740","http://www.chictr.org.cn/showproj.aspx?proj=49317",NA,"China","Beijing","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Viral Load or Clearance, Fever, Serious or Seconday Infections, Lymphocyte Count, IgG, IgM or IgA, SpO2, Respiratory Rate, Radiographic Findings","HCQ",78
"CHICTR2000030116","http://www.chictr.org.cn/showproj.aspx?proj=49901",NA,"China","Jiangxi","2020-Feb","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Severe","Hospitalized","Invasive Mechanical Ventilation or ECMO","Stem Cells",16
"CHICTR2000030088","http://www.chictr.org.cn/showproj.aspx?proj=49902",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Severe",NA,"Viral Load or Clearance, Radiographic Findings","Stem Cells",40
"CHICTR2000030117","http://www.chictr.org.cn/showproj.aspx?proj=49762",NA,"China","Beijing","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe",NA,"Viral Load or Clearance, Fever","Traditional Chinese Medicine",348
"CHICTR2000030054","http://www.chictr.org.cn/showproj.aspx?proj=49869",NA,"China","Fujian","2020-Feb","Not Recruiting","Randomized","Unspecified",3,"Confirmed","Non-severe",NA,"Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Serious Adverse Events, Heart Rate, Respiratory Rate","HCQ",100
"CHICTR2000029996","http://www.chictr.org.cn/showproj.aspx?proj=49510",NA,"China","Beijing","2020-Feb","Recruiting","Randomized","Open-Label",3,"Confirmed",NA,"Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Other Mild Symptoms","Favipiravir",60
"CHICTR2000030046","http://www.chictr.org.cn/showproj.aspx?proj=49861",NA,"China","Jiangxi","2020-Feb","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Mixed","Hospitalized","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Dyspnea, C-Reactive Protein, Lymphocyte Count, ALT, AST, Bilirubin, Antibodies, SpO2","Plasma Product",10
"CHICTR2000030041","http://www.chictr.org.cn/showproj.aspx?proj=49891",NA,"China","Hubei","2020-Feb","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospitalized","Viral Load or Clearance","Azivudine",40
"CHICTR2000030039","http://www.chictr.org.cn/showproj.aspx?proj=49544",NA,"China","Jiangsu","2020-Feb","Recruiting","Non-Randomized","Unspecified",2,"Confirmed","Mixed",NA,"Viral Load or Clearance, C-Reactive Protein, IL-6, LDH, Respiratory Rate, Renal Outcome (Unspecified)","Plasma Product",90
"NCT04275388","https://ClinicalTrials.gov/show/NCT04275388",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, PaO2-FiO2, SpO2, Respiratory Rate","Traditional Chinese Medicine",348
"CHICTR2000029992","http://www.chictr.org.cn/showproj.aspx?proj=49574",NA,"China","Fujian","2020-Feb","Not Recruiting","Randomized","Open-Label",3,"Confirmed","Severe",NA,"Hospital Discharge, Viral Load or Clearance, Fever, Serious Adverse Events, Respiratory Rate","HCQ",100
"CHICTR2000030010","http://www.chictr.org.cn/showproj.aspx?proj=49777",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Clinical Improvement Score (Any), Cough, Fever, Dyspnea, Other Mild Symptoms","Plasma",100
"CHICTR2000029989","http://www.chictr.org.cn/showproj.aspx?proj=49720",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"Viral Load or Clearance, Cough, Fever, Dyspnea, SpO2, Respiratory Rate, Radiographic Findings","Interferon Therapy",300
"CHICTR2000029988","http://www.chictr.org.cn/showproj.aspx?proj=49218",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events","HCQ",80
"CHICTR2000029990","http://www.chictr.org.cn/showproj.aspx?proj=49674",NA,"China","Beijing","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed",NA,"SpO2","Stem Cells",120
"NCT04269525","https://ClinicalTrials.gov/show/NCT04269525",NA,"China","Hubei","2020-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Procalcitonin, PaO2-FiO2, Radiographic Findings","Stem Cells",10
"CHICTR2000029935","http://www.chictr.org.cn/showproj.aspx?proj=49607",NA,"China","Zhejiang","2020-Feb","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,NA,"Mortality, Hospitalization, Clinical Improvement Score (Any), Secondary CoViD-19 Re-infection, Serious Adverse Events, C-Reactive Protein","HCQ",100
"CHICTR2000029939","http://www.chictr.org.cn/showproj.aspx?proj=49612",NA,"China","Zhejiang","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"Mortality, Hospitalization, Clinical Improvement Score (Any), Secondary CoViD-19 Re-infection, Fever, Serious Adverse Events, C-Reactive Protein, IL-2, IL-4, IL-6, IL-10, Tumor Necrosis Factor (Any), ALT, Bilirubin, Radiographic Findings","HCQ",100
"CHICTR2000029867","http://www.chictr.org.cn/showproj.aspx?proj=49514",NA,"China","Beijing","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Mixed","Viral Load or Clearance, Fever","Carriomycin",520
"CHICTR2000029853","http://www.chictr.org.cn/showproj.aspx?proj=49532",NA,"China","Henan","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality, Hospitalization, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, CD4, SpO2, Radiographic Findings","Azvudine",20
"CHICTR2000029850","http://www.chictr.org.cn/showproj.aspx?proj=49533",NA,"China","Zhejiang","2020-Feb","Recruiting","Non-Randomized","Unspecified",2,"Confirmed",NA,NA,"Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Anti SARS-COV-2 Titers, PaO2-FiO2","Plasma Product",20
"CHICTR2000029741","http://www.chictr.org.cn/showproj.aspx?proj=49263",NA,"China","Guangdong","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality, Hospitalization, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, IL-6, IL-10, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Neutrophils, Platelet Count, D-Dimer, Procalcitonin, Prothrombin, Fibrinogen, SpO2","HCQ,  LPV/r",112
"CHICTR2000029765","http://www.chictr.org.cn/showproj.aspx?proj=49409",NA,"China","Anhui","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed",NA,"Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","TCZ",188
"CHICTR2000029542","http://www.chictr.org.cn/showproj.aspx?proj=48968",NA,"China","Guangdong","2020-Feb","Recruiting","Non-Randomized","Unspecified",2,"Confirmed",NA,"Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein","HCQ",20
"CHICTR2000029541","http://www.chictr.org.cn/showproj.aspx?proj=48992",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Unspecified",3,"Confirmed",NA,"Hospitalized","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Radiographic Findings","Darunavir, LPV/r, Thymosin",100
"CHICTR2000029539","http://www.chictr.org.cn/showproj.aspx?proj=48991",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Cough, Fever, Dyspnea, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, SpO2, Respiratory Rate","LPV/r",328
"CHICTR2000029600","http://www.chictr.org.cn/showproj.aspx?proj=49042","https://reader.elsevier.com/reader/sd/pii/S2095809920300631?token=A28CA1B43E646EFBA54D61F15A05C13723D1BFA784EAC81E632C0FB769F1BD4BA964D4E304CB8D9EAA24DF528709668A","China","Guangdong","2020-Feb","Completed w. Results","Non-Randomized","Unspecified",3,"Confirmed",NA,NA,"Viral Load or Clearance, Radiographic Findings, Renal Outcome (Unspecified)","Favirapir, LPV/r",90
"CHICTR2000029572","http://www.chictr.org.cn/showproj.aspx?proj=41760",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Blood Gas, Radiographic Findings","Stem Cells",30
"CHICTR2000029569","http://www.chictr.org.cn/showproj.aspx?proj=49062",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Blood Gas, Radiographic Findings","Stem Cells",30
"CHICTR2000029559","http://www.chictr.org.cn/showproj.aspx?proj=48880","https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v1.full.pdf","China","Hubei","2020-Feb","Completed w. Results","Randomized","Double",3,"Confirmed",NA,NA,"Viral Load or Clearance, Lymphocyte Count, CD4, CD8","HCQ",300
"CHICTR2000029756","http://www.chictr.org.cn/showproj.aspx?proj=49222",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"ICU Admission, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Blood Gas, Blood Pressure, Heart Rate, Surfactant Factor Protein, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings","Traditional Chinese Medicine",238
"CHICTR2000029603","http://www.chictr.org.cn/showproj.aspx?proj=49075",NA,"China","Zhejiang","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, PaO2-FiO2, SpO2, Respiratory Rate","Asc09/Ritonavir",160
"CHICTR2000029606","http://www.chictr.org.cn/showproj.aspx?proj=49146",NA,"China","Zhejiang","2020-Feb","Recruiting","Randomized","Open-Label",5,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Stem Cells",63
"CHICTR2000029609","http://www.chictr.org.cn/showproj.aspx?proj=49145",NA,"China","Guangdong","2020-Feb","Not Recruiting","Non-Randomized","Open-Label",5,"Confirmed",NA,"Hospitalized","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance","HCQ , /- LPV/r",205
"CHICTR2000029621","http://www.chictr.org.cn/showproj.aspx?proj=49165",NA,"China","Shanghai","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe","Outpatients","Mortality, Viral Load or Clearance, Fever, Lymphocyte Count, SpO2","Arbidol",380
"CHICTR2000029548","http://www.chictr.org.cn/showproj.aspx?proj=49015",NA,"China","Zhejiang","2020-Feb","Not Recruiting","Randomized","Open-Label",3,"Confirmed","Non-severe",NA,"Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, ECG","Baloxavir, Marboxil, Favirapir, LPV/r",30
"CHICTR2000029400","http://www.chictr.org.cn/showproj.aspx?proj=48824",NA,"China","Beijing","2020-Jan","Recruiting","Non-Randomized","Unspecified",3,"Confirmed",NA,NA,"Viral Load or Clearance, Fever, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Hemoglobin, Erythrocyte Sedimentation Rate, Blood Gas, Radiographic Findings","Traditional Chinese Medicine",60
"CHICTR2000029468","http://www.chictr.org.cn/showproj.aspx?proj=48919",NA,"China","Sichuan","2020-Feb","Not Recruiting","Non-Randomized","Unspecified",2,"Confirmed",NA,NA,"Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS","Combination Antiviral",120
"NCT04261907","https://ClinicalTrials.gov/show/NCT04261907",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, PaO2-FiO2, SpO2, Respiratory Rate","Asc/Ritonavir, LPV/r",160
"NCT04260594","https://ClinicalTrials.gov/show/NCT04260594",NA,"China","Shanghai","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events, Serious Adverse Events, Lymphocyte Count, PaO2-FiO2, SpO2","Arbidol",380
"NCT04251871","https://ClinicalTrials.gov/show/NCT04251871",NA,"China","Beijing","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Dyspnea, Radiographic Findings","Traditional Chinese Medicine",150
"NCT04252885","https://ClinicalTrials.gov/show/NCT04252885","https://www.medrxiv.org/content/medrxiv/early/2020/03/23/2020.03.19.20038984.full.pdf","China","Guangdong","2020-Feb","Completed w. Results","Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, Tumor Necrosis Factor (Any), Interferon (Any), Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, ALT, AST, Bilirubin, Blood Pressure, Heart Rate, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings","LPV/r, Arbidol",125
"2020-000890-25","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000890-25/FR/","https://www.sciencedirect.com/science/article/pii/S0924857920300996","France","Paris","2020-Mar","Completed w. Results","Unspecified","Unspecified",NA,"Confirmed",NA,NA,"Mortality, Hospitalization, Viral Load or Clearance, Fever, Respiratory Rate","HCQ",NA
"2020-000936-23","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/FR/",NA,"France","Paris","2020-Mar","Recruiting","Randomised","Open-Label",4,"Confirmed",NA,"Hospitalized",NA,"LPV/r",NA
"2020-000982-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000982-18/NO/",NA,"Norway","Oslo","2020-Mar","Recruiting","Randomised","Open-Label",3,"Confirmed","Severe","ICU Or Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Treatment-emergent Adverse Events, eGFR, Quality of Life","HCQ, Remdesivir",NA
"2020-001023-14","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001023-14/GB/",NA,"United Kingdom","London","2020-Mar","Recruiting","Randomised","Double",2,"Confirmed",NA,"Hospitalized","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Respiratory Rate","Interferon Therapy",400
"2020-000919-69","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000919-69/NL/",NA,"Netherlands","Amsterdam","2020-Mar","Recruiting","Randomised","Double",2,"Healthy (Exposed)","None","Healthcare Workers","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS","BCG Vaccine",NA
"2020-001010-38","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001010-38/NO/",NA,"Norway","Oslo","2020-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ",NA
"2020-001162-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/DE/",NA,"Canada","Ottawa","2020-Mar","Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",440
"2020-001162-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/DE/",NA,"France","Paris","2020-Mar","Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",440
"2020-001162-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/DE/",NA,"Germany","Berlin","2020-Mar","Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",440
"2020-001162-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/DE/",NA,"Israel","Jerusalem","2020-Mar","Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",440
"2020-001162-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/DE/",NA,"Italy","Rome","2020-Mar","Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",440
"2020-001162-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/DE/",NA,"Japan","Tokyo","2020-Mar","Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",440
"2020-001162-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/DE/",NA,"Russia","Moscow","2020-Mar","Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",440
"2020-001162-12","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001162-12/DE/",NA,"Spain","Madrid","2020-Mar","Recruiting","Randomised","Double",3,"Confirmed","Severe","Hospitalized",NA,"Sarilumab",440
"2020-001156-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001156-18/ES/",NA,"Spain","Madrid","2020-Apr","Recruiting","Randomised","Open-Label",3,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Invasive Mechanical Ventilation or ECMO","HCQ",1000
"2020-001271-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001271-33/FR/",NA,"France","Paris","2020-Mar","Recruiting","Randomised","Double",2,"Confirmed","Unspecified","Unclear","Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-8, Tumor Necrosis Factor (Any), IgG, IgM or IgA, Antibodies","HCQ",NA
"2020-001442-19","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001442-19/ES/",NA,"Spain","Madrid","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU Or Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, C-Reactive Protein, White Blood Cell Count, Platelet Count, Hemoglobin, D-Dimer, Creatinine Phosphokinase, CK-MB, Troponin, Fibrinogen, ALT, AST, Bilirubin, Glucose, LDH","TCZ",NA
"2020-001606-33","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001606-33/ES/",NA,"Spain","Madrid","2020-Apr","Recruiting","Randomised","Open-Label",3,"Confirmed","Non-severe","Mixed","Mortality, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events, Treatment-emergent Adverse Events, Ferritin, D-Dimer, LDH, PaO2-FiO2, SpO2, Respiratory Rate","HCQ ,  Azithromycin",NA
"2020-001275-32","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001275-32/DK/",NA,"Denmark","Copenhagen","2020-Mar","Recruiting","Randomised","Open-Label",4,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, C-Reactive Protein","TCZ, Sarilumab",NA
"2020-001500-41","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001500-41/BE/",NA,"Belgium","Brussels","2020-Apr","Recruiting","Randomised","Open-Label",6,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-1, IL-6, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings, Hypoxia","Siltuximab, TCZ",NA
"2020-001270-29","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001270-29/DK/",NA,"Denmark","Copenhagen","2020-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospitalized","Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Fever, Adverse Events, Serious Adverse Events, PaO2-FiO2, SpO2","HCQ",350
"IRCT20200310046736N1","http://en.irct.ir/trial/46424",NA,"Iran","Golestan","2020-Apr","Not Recruiting","Randomized","Single",3,"Confirmed","Severe","ICU Or Hospitalized","Clinical Improvement Score (Any), Viral Load or Clearance","Plasma",45
"IRCT20100228003449N30","http://en.irct.ir/trial/46536",NA,"Iran","Tehran","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed Or Suspected",NA,"Hospitalized","Hospitalization, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events","HCQ ,  LPV/R ,  Oseltamivir",50
"IRCT20100228003449N28","http://en.irct.ir/trial/46538",NA,"Iran","Tehran","2020-Mar","Completed","Randomized","Open-Label",2,"Confirmed Or Suspected",NA,"Hospitalized","Hospitalization, Clinical Improvement Score (Any), Adverse Events","HCQ ,  Oseltamivir , LPV/r , IFN",30
"IRCT20100228003449N27","http://en.irct.ir/trial/46545",NA,"Iran","Tehran","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected",NA,"Hospitalized","Hospitalization, Clinical Improvement Score (Any), Adverse Events","HCQ ,  Oseltamivir , LPV/r ,  IFN",30
"IRCT20151227025726N12","http://en.irct.ir/trial/46561",NA,"Iran","Tehran","2020-Mar","Completed","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Hospitalization, Cough, Fever, Dyspnea, Other Mild Symptoms, Treatment-emergent Adverse Events, Radiographic Findings","HCQ, LPV/r,",20
"IRCT20100228003449N29","http://en.irct.ir/trial/46567",NA,"Iran","Tehran","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected",NA,"Hospitalized","Radiographic Findings, Renal Outcome (Unspecified)","Sofosbuvir/Lepdiasvir, HCQ , Oseltamivir, LPV/r",50
"IRCT20150914024017N1","http://en.irct.ir/trial/46665",NA,"Iran","Tehran","2020-Apr","Recruiting","Randomized","Triple",2,"Confirmed","Unspecified","Hospitalized","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Fever, Treatment-emergent Adverse Events, SpO2","Interferon Therapy",40
"IRCT20151227025726N13","http://en.irct.ir/trial/46681",NA,"Iran","Tehran","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospitalized","Hospitalization, Viral Load or Clearance, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, Radiographic Findings","TCZ, LPV/r, HCQ, oseltamivir",40
"IRCT20200324046850N5","http://en.irct.ir/trial/46751",NA,"Iran","Tehran","2020-Apr","Recruiting","Randomized","Double",2,"Confirmed","Unspecified","Unclear","Mortality, Hospitalization, Cough, Fever, SpO2, Respiratory Rate","Vitaminc C",40
"IRCT20200325046860N1","http://en.irct.ir/trial/46759",NA,"Iran","Tehran","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Respiratory Rate","Plasma",200
"JPRN- JAPICCTI-205238","https://rctportal.niph.go.jp/en/detail?trial_id= JAPICCTI-205238",NA,"Japan","Tokyo","2020-Mar","Recruiting","Randomized","Unspecified",NA,"Confirmed","Mixed","Hospitalized","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Adverse Events, Serious Adverse Events, SpO2, Radiographic Findings","FVP",96
"JPRN-JRCTS031190226","https://rctportal.niph.go.jp/en/detail?trial_id=JRCTS031190226",NA,"Japan","Gunma","2020-Feb","Recruiting","Unspecified","Open-Label",NA,"Confirmed",NA,"Hospitalized","Viral Load or Clearance, C-Reactive Protein","Favipiravir",50
"CHICTR2000029387","http://www.chictr.org.cn/showproj.aspx?proj=48782",NA,"China","Chongqing","2020-Jan","Recruiting","Randomized","Unspecified",3,"Confirmed","Mixed",NA,"Mortality, Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","LPV/r ,  Interferon",108
"CHICTR2000030254","http://www.chictr.org.cn/showproj.aspx?proj=50137","https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1.full.pdf","China","Hubei","2020-Feb","Completed w. Results","Randomized","Unspecified",2,"Confirmed",NA,"Hospitalized","Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Organ Failure or Dysfunction (SOFA), Serious Adverse Events","Favipiravir Vs. Arbidol",240
"JPRN-JRCTS041190120","https://jrct.niph.go.jp/latest-detail/jRCTs041190120",NA,"Japan","Aichi","2020-Feb","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,NA,"Viral Load or Clearance","Favipiravir",86
"EUCTR2020-001224-33-DE","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001224-33",NA,"Germany","Berlin","2020-Mar","Not Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ",220
"ACTRN12620000417987","https://anzctr.org.au/ACTRN12620000417987.aspx",NA,"Australia","Canberra","2020-Mar","Not Recruiting","Randomized","Open-Label",NA,"Healthy (Exposed)","None","Healthcare Workers","Clinical Improvement Score (Any), Viral Load or Clearance, Labor Absenteeism, Cough, Fever, Dyspnea, Other Mild Symptoms","HCQ",680
"EUCTR2020-001039-29-GR","https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001039-29",NA,"Greece","Athens","2020-Mar","Not Recruiting","Non-Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, Hospital Discharge, Clinical Improvement Score (Any), PaO2-FiO2, Radiographic Findings","TCZ, Anakinra,",40
"ACTRN12620000445976","https://anzctr.org.au/ACTRN12620000445976.aspx",NA,"Australia","Canberra","2020-Jun","Not Recruiting","Randomized","Open-Label",NA,"Confirmed","Mixed","Hospitalized",NA,"LPV/r, HCQ",2500
"ACTRN12620000445976","https://anzctr.org.au/ACTRN12620000445976.aspx",NA,"New Zealand","Wellington","2020-Jun","Not Recruiting","Randomized","Open-Label",NA,"Confirmed","Mixed","Hospitalized",NA,"LPV/r, HCQ",2500
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Argentina","Buenos Aires","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Brazil","Brasilia","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Canada","Ottawa","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Germany","Berlin","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Indonesia","Jakarta","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Iran","Tehran","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Norway","Oslo","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Peru","Lima","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Qatar","Doha","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"South Africa","Pretoria","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Spain","Madrid","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Switzerland","Bern","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN83971151","http://isrctn.com/ISRCTN83971151",NA,"Thailand","Nan","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Confirmed",NA,"Hospitalized",NA,"LPV/r, IFN, HCQ, remdesivir",10000
"ISRCTN86534580","http://isrctn.com/ISRCTN86534580",NA,"United Kingdom","London","2020-Mar","Recruiting","Randomized","Unspecified",NA,"Suspected",NA,"Outpatients","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","HCQ",3000
"ISRCTN50189673","http://isrctn.com/ISRCTN50189673",NA,"United Kingdom","London","2020-Feb","Recruiting","Randomized","Unspecified",NA,"Confirmed","Mixed","Hospitalized","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Renal Outcome (Unspecified)","LPV/r, IFN, HCQ, steroids",5000
"NL8490","https://trialregister.nl/trial/8490",NA,"Netherlands","Amsterdam","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Mixed","Mortality, ICU Admission, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","HCQ",950
"NCT04342689","https://ClinicalTrials.gov/show/NCT04342689",NA,"United States","Massachusetts","2020-Apr","Not Recruiting","Randomized","Quadruple",2,"Yes","Non-severe","Outpatients","Mortality, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Modified starch",1500
"NCT04335123","https://ClinicalTrials.gov/show/NCT04335123",NA,"United States","Kansas","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU Or Hospitalized","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Deep Vein Thrombosis or Pulmonary Embolism, Adverse Events, Treatment-emergent Adverse Events, Bicarbonates","Losartan",50
"NCT04341688","https://ClinicalTrials.gov/show/NCT04341688",NA,"Pakistan","Sind","2020-Apr","Not Recruiting","Randomized","Quadruple",2,"Yes","Unspecified","Not Specified","Mortality, ICU Admission, Hospital Discharge, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, C-Reactive Protein","Mouthwash",50
"NCT04326920","https://ClinicalTrials.gov/show/NCT04326920",NA,"Belgium","Brussels","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Adverse Events, Serious Adverse Events, PaO2-FiO2","Sargramostim",80
"NCT04348305","https://ClinicalTrials.gov/show/NCT04348305",NA,"Denmark","Copenhagen","2020-Apr","Recruiting","Randomized","Quadruple",2,"Yes","Severe","ICU Or Hospitalized",NA,"Corticosteroid(s)",1000
"NCT04350580","https://ClinicalTrials.gov/show/NCT04350580",NA,"France","Paris","2020-Apr","Recruiting","Randomized","Double",2,"Yes","Severe","ICU",NA,"Immunoglobulin",138
"NCT04335032","https://ClinicalTrials.gov/show/NCT04335032",NA,"Switzerland","Bern","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, IL-6, PaO2-FiO2, SpO2","Eicosapentaenoic acid",240
"NCT04344184","https://ClinicalTrials.gov/show/NCT04344184",NA,"United States","Virginia","2020-Apr","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Mixed","Hospitalized","Clinical Improvement Score (Any), Fever","Vitamin C",200
"NCT04311177","https://ClinicalTrials.gov/show/NCT04311177",NA,"United States","Minnesota","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed Or Suspected Or Exposed","Non-severe","Outpatients","Visits or Returns to Emergency Department","Losartan",580
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"United States","Florida","2020-Mar","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Aviptadil",120
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"United States","New York","2020-Mar","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Aviptadil",120
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"United States","Pennsylvania","2020-Mar","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Aviptadil",120
"NCT04311697","https://ClinicalTrials.gov/show/NCT04311697",NA,"Israel","Haifa","2020-Mar","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, PaO2-FiO2, Radiographic Findings, Hypoxia","Aviptadil",120
"NCT04345614","https://ClinicalTrials.gov/show/NCT04345614",NA,"United States","Michigan","2020-Apr","Recruiting","Randomized","Open-Label",2,"Yes","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","CM4620",120
"NCT04345614","https://ClinicalTrials.gov/show/NCT04345614",NA,"United States","Minnesota","2020-Apr","Recruiting","Randomized","Open-Label",2,"Yes","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","CM4620",120
"NCT04334629","https://ClinicalTrials.gov/show/NCT04334629",NA,"United Kingdom","London","2020-Apr","Not Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2","Ibuprofen",230
"NCT04341493","https://ClinicalTrials.gov/show/NCT04341493",NA,"Mexico","Mexico","2020-Apr","Recruiting","Randomized","Single",2,"Confirmed","Unspecified","Not Specified","Hospitalization","Nitazoxanide",86
"NCT04351906","https://ClinicalTrials.gov/show/NCT04351906",NA,"Germany","Hessen","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Yes","Severe","ICU",NA,"ECCO",20
"NCT04337918","https://ClinicalTrials.gov/show/NCT04337918",NA,"Canada","British Columbia","2020-Apr","Not Recruiting","Randomized","Single",2,"Confirmed","Mixed","Mixed","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Nitric oxide releasing solution",200
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","California","2020-Mar","Recruiting","Randomized","Single",2,"Confirmed",NA,"Outpatients","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine",6000
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"United States","New York","2020-Mar","Recruiting","Randomized","Single",2,"Confirmed",NA,"Outpatients","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine",6000
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"Canada","Quebec","2020-Mar","Recruiting","Randomized","Single",2,"Confirmed",NA,"Outpatients","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine",6000
"NCT04322682","https://ClinicalTrials.gov/show/NCT04322682",NA,"Spain","Madrid","2020-Mar","Recruiting","Randomized","Single",2,"Confirmed",NA,"Outpatients","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Blood pH","Colchicine",6000
"NCT04338958","https://ClinicalTrials.gov/show/NCT04338958",NA,"Germany","Berlin","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Viral Load or Clearance, Antibodies","Ruxolitinib",200
"NCT04348409","https://ClinicalTrials.gov/show/NCT04348409",NA,"Brazil","Brasilia","2020-Apr","Recruiting","Randomized","Quadruple",2,"Yes","Mixed","Hospitalized",NA,"Nitazoxanide",50
"NCT04346615","https://ClinicalTrials.gov/show/NCT04346615",NA,"United States","Pennsylvania","2020-Apr","Recruiting","Randomized","Quadruple",2,"Yes","Mixed","Hospitalized",NA,"Vazegepant",120
"NCT04342897","https://ClinicalTrials.gov/show/NCT04342897",NA,"United States","Indiana","2020-Apr","Recruiting","Randomized","Double",2,"Confirmed","Mixed","Hospitalized","Mortality, SpO2","LY3127804",200
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Florida","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO","Cd24f",230
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Georgia","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO","Cd24f",230
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Maryland","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO","Cd24f",230
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","New Jersey","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO","Cd24f",230
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Ohio","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO","Cd24f",230
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Pennsylvania","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO","Cd24f",230
"NCT04317040","https://ClinicalTrials.gov/show/NCT04317040",NA,"United States","Vermont","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO","Cd24f",230
"NCT04335786","https://ClinicalTrials.gov/show/NCT04335786",NA,"Netherlands","Amsterdam","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Mixed","Mixed","Mortality, ICU Admission, Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation","Valsartan",651
"NCT04312009","https://ClinicalTrials.gov/show/NCT04312009",NA,"United States","Minnesota","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed Or Suspected","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Dyspnea, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, SpO2","Losartan",200
"NCT04320277","https://ClinicalTrials.gov/show/NCT04320277",NA,"Italy","Prato","2020-Mar","Not Recruiting","Non-Randomized","Open-Label",2,"Confirmed","Mixed",NA,"ICU Admission, Adverse Events, C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any)","Baricitinib",200
"NCT04325906","https://ClinicalTrials.gov/show/NCT04325906",NA,"United States","Illinois","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","ICU",NA,"High nasal flow cannula",346
"NCT04344431","https://ClinicalTrials.gov/show/NCT04344431",NA,"France","Paris","2020-Apr","Recruiting","Randomized","Single",2,"Confirmed","Mixed","Mixed","Mortality, Hospitalization, Non-invasive Ventilation","Hyperbaric oxygen",100
"NCT04341675","https://ClinicalTrials.gov/show/NCT04341675",NA,"United States","Ohio","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Mixed","Hospitalized",NA,"Sirolimus",30
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Illinois","2020-Apr","Recruiting","Randomized","Quadruple",2,"Yes","Severe","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO","TJ003234",144
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Indiana","2020-Apr","Recruiting","Randomized","Quadruple",2,"Yes","Severe","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO","TJ003234",144
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Louisiana","2020-Apr","Recruiting","Randomized","Quadruple",2,"Yes","Severe","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO","TJ003234",144
"NCT04341116","https://ClinicalTrials.gov/show/NCT04341116",NA,"United States","Mississippi","2020-Apr","Recruiting","Randomized","Quadruple",2,"Yes","Severe","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO","TJ003234",144
"NCT04351490","https://ClinicalTrials.gov/show/NCT04351490",NA,"France","Paris","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Yes","Severe","Hospitalized",NA,"Zinc, Vitamin D",3140
"NCT04323345","https://ClinicalTrials.gov/show/NCT04323345",NA,"Egypt","Cairo","2020-Mar","Recruiting","Randomized","Single",2,"Confirmed",NA,NA,"Mortality, Viral Load or Clearance, Fever, Radiographic Findings","Nutritional Support",1000
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","California","2020-Apr","Recruiting","Randomized","Single",2,"Yes","Severe","Hospitalized",NA,"Selinexor",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Kentucky","2020-Apr","Recruiting","Randomized","Single",2,"Yes","Severe","Hospitalized",NA,"Selinexor",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Pennsylvania","2020-Apr","Recruiting","Randomized","Single",2,"Yes","Severe","Hospitalized",NA,"Selinexor",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"United States","Texas","2020-Apr","Recruiting","Randomized","Single",2,"Yes","Severe","Hospitalized",NA,"Selinexor",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"Austria","Vienna","2020-Apr","Recruiting","Randomized","Single",2,"Yes","Severe","Hospitalized",NA,"Selinexor",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"Israel","Jerusalem","2020-Apr","Recruiting","Randomized","Single",2,"Yes","Severe","Hospitalized",NA,"Selinexor",230
"NCT04349098","https://ClinicalTrials.gov/show/NCT04349098",NA,"Spain","Salamanca","2020-Apr","Recruiting","Randomized","Single",2,"Yes","Severe","Hospitalized",NA,"Selinexor",230
"NCT04344041","https://ClinicalTrials.gov/show/NCT04344041",NA,"France","Paris","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Mixed","Invasive Mechanical Ventilation or ECMO","Vitamin D",260
"NCT04343729","https://ClinicalTrials.gov/show/NCT04343729",NA,"Brazil","Amazonas","2020-Apr","Recruiting","Randomized","Quadruple",2,"Suspected","Mixed","Mixed","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Corticosteroid(s)",420
"NCT04320056","https://ClinicalTrials.gov/show/NCT04320056",NA,"Canada","Quebec","2020-Mar","Recruiting","Randomized","Open-Label",2,"Suspected","Severe","Hospitalized","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Oxygen",216
"NCT04343001","https://ClinicalTrials.gov/show/NCT04343001",NA,"Nigeria","Niger","2020-Apr","Not Recruiting","Randomized","Open-Label",3,"Presumed","Mixed","Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Aspirin, losartan, simvastatin",10000
"NCT04343001","https://ClinicalTrials.gov/show/NCT04343001",NA,"Pakistan","Islamabad","2020-Apr","Not Recruiting","Randomized","Open-Label",3,"Presumed","Mixed","Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Aspirin, losartan, simvastatin",10000
"NCT04343989","https://ClinicalTrials.gov/show/NCT04343989",NA,"United States","New York","2020-Apr","Recruiting","Randomized","Double",3,"Confirmed","Severe","Hospitalized","Non-invasive Ventilation","Clazakizumab",90
"NCT04344288","https://ClinicalTrials.gov/show/NCT04344288",NA,"France","Paris","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events","Corticosteroid(s)",304
"NCT04344288","https://ClinicalTrials.gov/show/NCT04344288",NA,"France","Nord","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events","Corticosteroid(s)",304
"NCT04344288","https://ClinicalTrials.gov/show/NCT04344288",NA,"France","Vienne","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events","Corticosteroid(s)",304
"NCT04326426","https://ClinicalTrials.gov/show/NCT04326426",NA,"United States","New York","2020-Mar","Recruiting","Randomized","Triple",2,"Confirmed","Severe","Hospitalized","Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, IL-6, SpO2","Tradipitant",300
"CHICTR2000029976","http://www.chictr.org.cn/showproj.aspx?proj=49631",NA,"China","Shanghai","2020-Feb","Recruiting","Non-Randomized","Open-Label",2,"Confirmed","Non-severe",NA,"Non-invasive Ventilation, Cough, Dyspnea, Other Mild Symptoms, Radiographic Findings, Quality of Life","Traditional Chinese Medicine",160
"NCT04350593","https://ClinicalTrials.gov/show/NCT04350593",NA,"United States","Missouri","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Mixed","Hospitalized",NA,"Dapagliflozin",900
"NCT04348071","https://ClinicalTrials.gov/show/NCT04348071",NA,"United States","Colorado","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospitalized",NA,"Ruxolitinib",80
"NCT04346199","https://ClinicalTrials.gov/show/NCT04346199",NA,"Spain","Barcelona","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized",NA,"Acalabrutinib",428
"NCT04351763","https://ClinicalTrials.gov/show/NCT04351763",NA,"Poland","Warsaw","2020-Apr","Recruiting","Randomized","Single",2,"Confirmed","Mixed","Hospitalized",NA,"Amiodarone, Verapamil",804
"NCT04347174","https://ClinicalTrials.gov/show/NCT04347174",NA,"India","Chandigarh","2020-Apr","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized",NA,"Treated mycobacterium",40
"NCT04329650","https://ClinicalTrials.gov/show/NCT04329650",NA,"Spain","Madrid","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, Viral Load or Clearance, Treatment-emergent Adverse Events","Siltuximab",200
"NCT04329650","https://ClinicalTrials.gov/show/NCT04329650",NA,"Spain","Barcelona","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, Viral Load or Clearance, Treatment-emergent Adverse Events","Siltuximab",200
"NCT04329650","https://ClinicalTrials.gov/show/NCT04329650",NA,"Spain","Salamanca","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, Viral Load or Clearance, Treatment-emergent Adverse Events","Siltuximab",200
"NCT04348383","https://ClinicalTrials.gov/show/NCT04348383",NA,"Spain","Murcia","2020-Apr","Recruiting","Randomized","Double",2,"Confirmed","Severe","Hospitalized",NA,"Defibrotide",120
"NCT04350320","https://ClinicalTrials.gov/show/NCT04350320",NA,"Spain","Murcia","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized",NA,"Colchicine",102
"NCT04344782","https://ClinicalTrials.gov/show/NCT04344782",NA,"France","Paris","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Yes","Mixed","Hospitalized","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Fever, Blood Pressure, Heart Rate","Bevacizumab",130
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Barcelona","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroid(s)",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Las Palmas","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroid(s)",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Madrid","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroid(s)",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Ciudad Real","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroid(s)",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Murcia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroid(s)",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Pontevedra","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroid(s)",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Valencia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroid(s)",200
"NCT04325061","https://ClinicalTrials.gov/show/NCT04325061",NA,"Spain","Valladolid","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Corticosteroid(s)",200
"NCT04334044","https://ClinicalTrials.gov/show/NCT04334044",NA,"Mexico","Mexico","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,NA,"Mortality, ICU Admission, Pneumonia or ARDS, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, D-Dimer","Ruxolitinib",20
"NCT04351152","https://ClinicalTrials.gov/show/NCT04351152",NA,"United States","California","2020-Apr","Not Recruiting","Randomized","Double",2,"Yes","Mixed","Hospitalized",NA,"Lenziulumab",238
"NCT04331054","https://ClinicalTrials.gov/show/NCT04331054",NA,"France","Paris","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized","Hospitalization, Viral Load or Clearance, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Corticosteroid(s)",436
"NCT04273321","https://ClinicalTrials.gov/show/NCT04273321",NA,"China","Hubei","2020-Feb","Suspended","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospitalized",NA,"Corticosteroid(s)",400
"NCT04273321","https://ClinicalTrials.gov/show/NCT04273321",NA,"China","Beijing","2020-Feb","Suspended","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospitalized",NA,"Corticosteroid(s)",400
"NCT04319731","https://ClinicalTrials.gov/show/NCT04319731",NA,"United States","Utah","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospitalized","Mortality, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, IL-6","Amniotic Fluid",10
"NCT04348695","https://ClinicalTrials.gov/show/NCT04348695",NA,"Spain","Madrid","2020-Apr","Recruiting","Randomized","Open-Label",2,"Yes","Mixed","Hospitalized","ICU Admission, Hospitalization, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Simvastatin, ruxolitinib",94
"NCT04342728","https://ClinicalTrials.gov/show/NCT04342728",NA,"United States","Ohio","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Yes","Non-severe","Outpatients","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation","Vitamin C, Zinc",520
"CHICTR2000029433","http://www.chictr.org.cn/showproj.aspx?proj=48898",NA,"China","Hebei","2020-Feb","Completed","Randomized","Open-Label",2,"Suspected",NA,NA,"Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Radiographic Findings","Traditional Chinese Medicine",240
"CHICTR2000029434","http://www.chictr.org.cn/showproj.aspx?proj=48889",NA,"China","Hebei","2020-Feb","Completed","Randomized","Open-Label",2,"Confirmed","Non-severe",NA,"Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Radiographic Findings","Traditional Chinese Medicine",240
"CHICTR2000032011","http://www.chictr.org.cn/showproj.aspx?proj=52142",NA,"China","Beijing","2020-Apr","Not Recruiting","Randomized","Unspecified",3,"Yes","Severe","Hospitalized",NA,"Hyperbaric oxygen",45
"NCT04333420","https://ClinicalTrials.gov/show/NCT04333420",NA,"Netherlands","Amsterdam","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Viral Load or Clearance, PaO2-FiO2","IFX1",130
"NCT04348500","https://ClinicalTrials.gov/show/NCT04348500",NA,"United States","California","2020-Apr","Not Recruiting","Randomized","Quadruple",2,"Yes","Severe","Hospitalized",NA,"Clazakizumab",60
"NCT04343248","https://ClinicalTrials.gov/show/NCT04343248",NA,"United States","Florida","2020-Apr","Not Recruiting","Randomized","Triple",2,"Not Specified","Unspecified","Prophylaxis","Mortality, Clinical Improvement Score (Any), PaO2-FiO2","Nitazoxanide",600
"NCT04346147","https://ClinicalTrials.gov/show/NCT04346147",NA,"Spain","Madrid","2020-Apr","Not Recruiting","Randomized","Open-Label",4,"Yes","Unspecified","Mixed",NA,"HCQ, LPV/r, Baricitinib",165
"NCT04348513","https://ClinicalTrials.gov/show/NCT04348513",NA,"Greece","Athens","2020-Apr","Not Recruiting","Randomized","Triple",2,"Yes","Severe","ICU",NA,"T3",60
"NCT04341285","https://ClinicalTrials.gov/show/NCT04341285",NA,"Germany","Berlin","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Yes","Severe","ICU","Mortality, Invasive Mechanical Ventilation or ECMO","ECMO",200
"NCT04323228","https://ClinicalTrials.gov/show/NCT04323228",NA,"Saudi Arabia","Riyadh","2020-Mar","Not Recruiting","Randomized","Double",2,"Confirmed","Non-severe",NA,"Non-invasive Ventilation, Fever, C-Reactive Protein, Ferritin, IL-6, Tumor Necrosis Factor (Any), MCP-1, White Blood Cell Count, Lymphocyte Count, Neutrophils, Weight, Height or BMI","Nutritional Support",30
"NCT04315987","https://ClinicalTrials.gov/show/NCT04315987",NA,"Brazil","Brasilia","2020-Mar","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Mortality, Clinical Improvement Score (Any), Non-invasive Ventilation, White Blood Cell Count, Lymphocyte Count, Creatinine Phosphokinase, CK-MB, ALT, AST, CD4, CD8, PaO2-FiO2","Nestcell",66
"NCT04244591","https://ClinicalTrials.gov/show/NCT04244591",NA,"China","Beijing","2020-Jan","Completed","Randomized","Open-Label",2,"Confirmed","Severe","ICU","Mortality, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), SpO2, Radiographic Findings","Corticosteroid(s)",80
"NCT04344756","https://ClinicalTrials.gov/show/NCT04344756",NA,"France","Paris","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Mixed","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Pneumonia or ARDS, Non-invasive Ventilation, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism, Bicarbonates","Tinzaparin",808
"NCT04342663","https://ClinicalTrials.gov/show/NCT04342663",NA,"United States","Illinois","2020-Apr","Recruiting","Randomized","Triple",2,"Yes","Mild","Outpatients","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Troponin","Fluvoxamine",152
"NCT04342663","https://ClinicalTrials.gov/show/NCT04342663",NA,"United States","Missouri","2020-Apr","Recruiting","Randomized","Triple",2,"Yes","Mild","Outpatients","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, Troponin","Fluvoxamine",152
"NCT04343963","https://ClinicalTrials.gov/show/NCT04343963",NA,"Mexico","Mexico","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Moderate/severe","Hospitalized","Mortality, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, IL-6","Pyridostigmine Bromide",436
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Bahia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Mixed",NA,NA,"Corticosteroid(s)",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Distrito Federal","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Mixed",NA,NA,"Corticosteroid(s)",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Brasilia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Mixed",NA,NA,"Corticosteroid(s)",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Minas Gerais","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Mixed",NA,NA,"Corticosteroid(s)",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Para","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Mixed",NA,NA,"Corticosteroid(s)",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Rio Grande Do Norte","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Mixed",NA,NA,"Corticosteroid(s)",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Rio Grande Do Sul","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Mixed",NA,NA,"Corticosteroid(s)",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Brazil","Santa Catarina","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Mixed",NA,NA,"Corticosteroid(s)",290
"NCT04327401","https://ClinicalTrials.gov/show/NCT04327401",NA,"Israel","Jerusalem","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Mixed",NA,NA,"Corticosteroid(s)",290
"NCT04345887","https://ClinicalTrials.gov/show/NCT04345887",NA,"Turkey","Istanbul","2020-Apr","Not Recruiting","Randomized","Triple",2,"Yes","Severe","ICU",NA,"Spironolactone",60
"NCT04322565","https://ClinicalTrials.gov/show/NCT04322565",NA,"Italy","Parma","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Outpatients","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Fever","Colchicine",310
"NCT04325633","https://ClinicalTrials.gov/show/NCT04325633",NA,"France","Paris","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, Clinical Improvement Score (Any), .","Naproxen",584
"NCT04331366","https://ClinicalTrials.gov/show/NCT04331366",NA,"United States","Georgia","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospitalized","Blood Pressure, Heart Rate, ECG, SpO2, Blood pH, Bicarbonates","Bidirectional oxygen",5
"NCT04344080","https://ClinicalTrials.gov/show/NCT04344080",NA,"Germany","Hamburg","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Unclear","Mortality, ICU Admission, Non-invasive Ventilation, Serious or Seconday Infections, C-Reactive Protein, IL-7, PD-1, Creatinine Phosphokinase, Bicarbonates","Cytosorb",24
"NCT04344236","https://ClinicalTrials.gov/show/NCT04344236",NA,"United States","New York","2020-Apr","Recruiting","Randomized","Open-Label",3,"Confirmed","Mild","Unclear","Viral Load or Clearance, Pneumonia or ARDS, Heart Rate","Nasal rinses",48
"NCT04313023","https://ClinicalTrials.gov/show/NCT04313023",NA,"China","Beijing","2020-Mar","Not Recruiting","Randomized","Quadruple",2,"Healthy (Exposed)","None","Healthy (Exposed)","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation","Pul-042",200
"NCT04312997","https://ClinicalTrials.gov/show/NCT04312997",NA,"United States","Texas","2020-Mar","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Unspecified","Observation","Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation","Pul-042",100
"NCT04344730","https://ClinicalTrials.gov/show/NCT04344730",NA,"France","Paris","2020-Apr","Recruiting","Randomized","Quadruple",6,"Confirmed Or Suspected","Severe","ICU","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Hypoxemia, Cardiac Outcome (Unspecified)","O2 support, corticosteroids",550
"NCT04343144","https://ClinicalTrials.gov/show/NCT04343144",NA,"France","Paris","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Moderate","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Adverse Events, Serious Adverse Events","Nivolumab",92
"NCT04345276","https://ClinicalTrials.gov/show/NCT04345276",NA,"China","Hubei","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Moderate","Hospitalized","ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious Adverse Events","Danoprevir, ritonavir",40
"NCT04329195","https://ClinicalTrials.gov/show/NCT04329195",NA,"France","Paris","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized","Mortality, Clinical Improvement Score (Any), Serious Adverse Events","Discontinuation of RAS",554
"NCT04343651","https://ClinicalTrials.gov/show/NCT04343651",NA,"United States","New York","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Mild or moderate","Mixed","Adverse Events, Natural Killer Cell Count","Leronimab",75
"NCT04345406","https://ClinicalTrials.gov/show/NCT04345406",NA,"Egypt","Cairo","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Unspecified","Unclear","Viral Load or Clearance, Lymphocyte Count, Radiographic Findings","ACE Inhibitors",60
"NCT04344561","https://ClinicalTrials.gov/show/NCT04344561",NA,"United States","Maryland","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance","Posutral positioning",70
"NCT04344106","https://ClinicalTrials.gov/show/NCT04344106",NA,"France","Paris","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","ICU Or Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Serious Adverse Events, SpO2","Prone positioning",25
"NCT04344548","https://ClinicalTrials.gov/show/NCT04344548",NA,"Colombia","Bogota","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Moderate or severe","Hospitalized","ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Household Members with CoViD-19, Labor Absenteeism, Adverse Events, Treatment-emergent Adverse Events","NK cells",10
"NCT04344548","https://ClinicalTrials.gov/show/NCT04344548",NA,"Colombia","Cundinamarca","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Moderate or severe","Hospitalized","ICU Admission, Hospitalization, Hospital Discharge, Viral Load or Clearance, Household Members with CoViD-19, Labor Absenteeism, Adverse Events, Treatment-emergent Adverse Events","NK cells",10
"NCT04341584","https://ClinicalTrials.gov/show/NCT04341584",NA,"France","Paris","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","ICU Or Hospitalized","Mortality, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Anakinra",240
"NCT04280224","https://ClinicalTrials.gov/show/NCT04280224",NA,"China","Henan","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Viral Load or Clearance, Treatment-emergent Adverse Events, CD4, CD8, Radiographic Findings","Natural-Killer Cells",30
"NCT04343183","https://ClinicalTrials.gov/show/NCT04343183",NA,"United States","Louisiana","2020-Apr","Not Recruiting","Randomized","Single",2,"Confirmed","Moderate/severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation","Hyperbaric oxygen",48
"NCT04331665","https://ClinicalTrials.gov/show/NCT04331665",NA,"Canada","Ontario","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,NA,"Hospitalization, Viral Load or Clearance, Fever, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Ruxolitinib",64
"NCT04330300","https://ClinicalTrials.gov/show/NCT04330300",NA,"Ireland","Galway","2020-Apr","Recruiting","Randomized","Open-Label",4,"Healthy",NA,"Healthy","Viral Load or Clearance, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Antihpyertensives",2414
"NCT04252274","https://ClinicalTrials.gov/show/NCT04252274",NA,"China","Shanghai","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","Darunavir And Cobicistat",30
"NCT04342221","https://ClinicalTrials.gov/show/NCT04342221",NA,"Germany","Berlin","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitaliezd","Mortality, Invasive Mechanical Ventilation or ECMO","HCQ",220
"NCT04341038","https://ClinicalTrials.gov/show/NCT04341038",NA,"Spain","Barcelona","2020-Apr","Recruiting","Randomized","Single",2,"Confirmed","Severe","ICU","Mortality, Invasive Mechanical Ventilation or ECMO","Corticosteroids, tacrolimus",84
"NCT04341935","https://ClinicalTrials.gov/show/NCT04341935",NA,"United States","Florida","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mild or moderate","Mixed","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","Linagliptin",20
"NCT04340232","https://ClinicalTrials.gov/show/NCT04340232",NA,"United States","Colorado","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Baricitinib",80
"NCT04332081","https://ClinicalTrials.gov/show/NCT04332081",NA,"United States","New York","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Hyperbaric oxygen",40
"NCT04324021","https://ClinicalTrials.gov/show/NCT04324021",NA,"Italy","Brescia","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed",NA,"ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emapalumab, Anakinra",54
"NCT04324021","https://ClinicalTrials.gov/show/NCT04324021",NA,"Italy","Milano","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed",NA,"ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emapalumab, Anakinra",54
"NCT04324021","https://ClinicalTrials.gov/show/NCT04324021",NA,"Italy","Parma","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed",NA,"ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emapalumab, Anakinra",54
"NCT04324021","https://ClinicalTrials.gov/show/NCT04324021",NA,"Italy","Roma","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed",NA,"ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Emapalumab, Anakinra",54
"NCT04305457","https://ClinicalTrials.gov/show/NCT04305457",NA,"United States","Massachusetts","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Nitric Oxide",240
"NCT04340414","https://ClinicalTrials.gov/show/NCT04340414",NA,"China","Beijing","2020-Apr","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Low flow ECMO",10
"NCT04340557","https://ClinicalTrials.gov/show/NCT04340557",NA,"United States","California","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mild or moderate","Mixed","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events, C-Reactive Protein, Ferritin, IL-6","Losartan",200
"NCT04338828","https://ClinicalTrials.gov/show/NCT04338828",NA,"United States","Massachusetts","2020-Apr","Not Recruiting","Randomized","Triple",2,"Suspected","Mixed","Mixed","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, SpO2","Nitric oxide, oxygen",260
"NCT04338074","https://ClinicalTrials.gov/show/NCT04338074",NA,"United States","Alabama","2020-Apr","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Mixed","Outpatients","Viral Load or Clearance, Treatment-emergent Adverse Events","Tranexamic acid",100
"NCT04338126","https://ClinicalTrials.gov/show/NCT04338126",NA,"United States","Alabama","2020-Apr","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Unspecified","Hospitalized","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms","Tranexamic acid",60
"NCT04338802","https://ClinicalTrials.gov/show/NCT04338802",NA,"China","Hubei","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Nintedanib",96
"NCT04336462","https://ClinicalTrials.gov/show/NCT04336462",NA,"China","Guangdong","2020-Apr","Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, C-Reactive Protein, White Blood Cell Count, Lymphocyte Count, Neutrophils, Platelet Count, Hemoglobin, Urine Sample, IgG, IgM or IgA, Blood Urea Nitrogen","Hydrogen ,  oxygen",100
"NCT04337541","https://ClinicalTrials.gov/show/NCT04337541",NA,"Denmark","Copenhagen","2020-Apr","Recruiting","Randomized","Open-Label",2,"Healthy","Non-severe","Healthy","Viral Load or Clearance, Antibodies","Surgical facial mask",6000
"NCT04334005","https://ClinicalTrials.gov/show/NCT04334005",NA,"Spain","Granada","2020-Apr","Not Recruiting","Randomized","Double",2,"Confirmed","Non-severe","Outpatients","Mortality, ICU Admission, Hospitalization, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms","Vitamin D",200
"NCT04306393","https://ClinicalTrials.gov/show/NCT04306393",NA,"United States","Alabama","2020-Mar","Recruiting","Randomized","Single",2,"Confirmed","Severe","ICU",NA,"Nitric Oxide",200
"NCT04306393","https://ClinicalTrials.gov/show/NCT04306393",NA,"United States","Louisiana","2020-Mar","Recruiting","Randomized","Single",2,"Confirmed","Severe","ICU",NA,"Nitric Oxide",200
"NCT04306393","https://ClinicalTrials.gov/show/NCT04306393",NA,"United States","Massachusetts","2020-Mar","Recruiting","Randomized","Single",2,"Confirmed","Severe","ICU",NA,"Nitric Oxide",200
"NCT04333550","https://ClinicalTrials.gov/show/NCT04333550",NA,"Iran","Kermanshah","2020-Apr","Recruiting","Randomized","Double",2,"Confirmed","Mixed","Mixed","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, Lymphocyte Count, PaO2-FiO2","Deferoxamine",50
"NCT04335136","https://ClinicalTrials.gov/show/NCT04335136",NA,"Austria","Vienna","2020-Apr","Not Recruiting","Randomized","Double",2,"Confirmed","Unspecified","Mixed",NA,"Recombinant ACE",200
"NCT04335136","https://ClinicalTrials.gov/show/NCT04335136",NA,"Austria","Wien","2020-Apr","Not Recruiting","Randomized","Double",2,"Confirmed","Unspecified","Mixed",NA,"Recombinant ACE",200
"NCT04335136","https://ClinicalTrials.gov/show/NCT04335136",NA,"Denmark","Copenhagen","2020-Apr","Not Recruiting","Randomized","Double",2,"Confirmed","Unspecified","Mixed",NA,"Recombinant ACE",200
"NCT04335136","https://ClinicalTrials.gov/show/NCT04335136",NA,"Germany","Hamburg","2020-Apr","Not Recruiting","Randomized","Double",2,"Confirmed","Unspecified","Mixed",NA,"Recombinant ACE",200
"NCT04335136","https://ClinicalTrials.gov/show/NCT04335136",NA,"Germany","Berlin","2020-Apr","Not Recruiting","Randomized","Double",2,"Confirmed","Unspecified","Mixed",NA,"Recombinant ACE",200
"NCT04335201","https://ClinicalTrials.gov/show/NCT04335201",NA,"Italy","Milano","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), LDH","Defibrotide",50
"NCT04334460","https://ClinicalTrials.gov/show/NCT04334460",NA,"United States","California","2020-Apr","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Hospital Discharge, Viral Load or Clearance, Non-invasive Ventilation, Fever, Treatment-emergent Adverse Events, Serious Adverse Events, IL-6, PaO2-FiO2, SpO2","BLD-2660",120
"NCT04332666","https://ClinicalTrials.gov/show/NCT04332666",NA,"Belgium","Brussels","2020-Apr","Not Recruiting","Randomized","Triple",2,"Confirmed Or Suspected",NA,"ICU","ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Deep Vein Thrombosis or Pulmonary Embolism, Serious Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), Angiotensins, PaO2-FiO2, Radiographic Findings","Angiotensin",60
"NCT04321096","https://ClinicalTrials.gov/show/NCT04321096",NA,"Denmark","Copenhagen","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed",NA,"Hospitalized","Mortality, ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Camostat",180
"CHICTR2000031630","http://www.chictr.org.cn/showproj.aspx?proj=50474",NA,"China","Guangdong","2020-Apr","Recruiting","Non-Randomized","Unspecified",2,"Confirmed","Unspecified","Unclear",NA,"Celecoxib",60
"NCT04333472","https://ClinicalTrials.gov/show/NCT04333472",NA,"Israel","Jerusalem","2020-Apr","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized","Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, PaO2-FiO2","Piclidenoson",40
"NCT04275414","https://ClinicalTrials.gov/show/NCT04275414",NA,"China","Hubei","2020-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"Bevacizumab",20
"NCT04275414","https://ClinicalTrials.gov/show/NCT04275414",NA,"China","Shandong","2020-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"Bevacizumab",20
"NCT04275414","https://ClinicalTrials.gov/show/NCT04275414",NA,"Italy","Rome","2020-Feb","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"Bevacizumab",20
"NCT04312243","https://ClinicalTrials.gov/show/NCT04312243",NA,"China","Beijing","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Healthy (Exposed)","None","Healthcare Workers","Viral Load or Clearance, Labor Absenteeism","Nitric Oxide",470
"NCT04324489","https://ClinicalTrials.gov/show/NCT04324489",NA,"China","Hubei","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Mortality, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation","Antiviral",4
"NCT04326790","https://ClinicalTrials.gov/show/NCT04326790",NA,"Greece","Athens","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Clinical Improvement Score (Any), C-Reactive Protein, Troponin","Colchicine",180
"NCT04332042","https://ClinicalTrials.gov/show/NCT04332042",NA,"Italy","Ancona","2020-Apr","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed",NA,"Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Tofacitinib",50
"NCT04326452","https://ClinicalTrials.gov/show/NCT04326452",NA,"United States","Arizona","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"Bidirectional oxygen",15
"NCT04326452","https://ClinicalTrials.gov/show/NCT04326452",NA,"United States","California","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"Bidirectional oxygen",15
"NCT04326452","https://ClinicalTrials.gov/show/NCT04326452",NA,"United States","Georgia","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized",NA,"Bidirectional oxygen",15
"NCT04328480","https://ClinicalTrials.gov/show/NCT04328480",NA,"Uruguay","Montevideo","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Severe","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","Colchicine",2500
"NCT04327505","https://ClinicalTrials.gov/show/NCT04327505",NA,"Sweden","Stockholm","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Severe",NA,"Mortality, ICU Admission, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Serious or Seconday Infections, Adverse Events, Serious Adverse Events, Peak RC-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Procalcitonin","Hyperbaric oxygen",200
"NCT04326075","https://ClinicalTrials.gov/show/NCT04326075",NA,"Italy","Milan","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected",NA,"Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO","CPAP",900
"NCT04288713","https://ClinicalTrials.gov/show/NCT04288713",NA,"United States","New York","2020-Feb","Recruiting","Unspecified","Unspecified",NA,"Confirmed","Severe","ICU",NA,"Eculizumab",NA
"NCT04326114","https://ClinicalTrials.gov/show/NCT04326114",NA,"Spain","Madrid","2020-Mar","Not Recruiting","Randomized","Single",2,"Healthy",NA,"Healthy","Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events","Inspiratory/expiratory training device",240
"CHICTR2000031203","http://www.chictr.org.cn/showproj.aspx?proj=51030",NA,"China","Henan","2020-Mar","Recruiting","Randomized","Unspecified",2,"Resolved",NA,"Discharged","Anxiety","Traditional Chinese Medicine",28
"NCT04324996","https://ClinicalTrials.gov/show/NCT04324996",NA,"China","Chongqing","2020-Mar","Recruiting","Randomized","Quadruple",2,"Confirmed",NA,NA,"Clinical Improvement Score (Any), Pneumonia or ARDS, Adverse Events, Treatment-emergent Adverse Events","Engineered Cells",90
"NCT04321928","https://ClinicalTrials.gov/show/NCT04321928",NA,"China","Beijing","2020-Mar","Not Recruiting","Randomized","Double",2,"Healthy","None","Healthy","ICU Admission, Hospitalization, Other Mild Symptoms","Behavioral",7576
"NCT04323592","https://ClinicalTrials.gov/show/NCT04323592",NA,"Italy","Trieste","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein","Corticosteroid(s)",104
"NCT04322344","https://ClinicalTrials.gov/show/NCT04322344",NA,"Italy","Catanzaro","2020-Mar","Recruiting","Non-Randomized","Double",2,"Confirmed",NA,"Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Escin",120
"CHICTR2000030198","http://www.chictr.org.cn/showproj.aspx?proj=50066",NA,"China","Sichuan","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Resolved","Severe","Discharged","Clinical Improvement Score (Any), PaO2-FiO2, SpO2, Respiratory Rate, 6-Minute Walking Distance, Quality of Life, Depression, Anxiety","Educational",60
"NCT04323332","https://ClinicalTrials.gov/show/NCT04323332",NA,"China","Beijing","2020-Mar","Not Recruiting","Non-Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Adverse Events, C-Reactive Protein, Ferritin, IL-6, White Blood Cell Count, Lymphocyte Count, Neutrophils, Platelet Count, Erythrocyte Sedimentation Rate, D-Dimer, Creatinine Phosphokinase, CK-MB, AST, LDH, Antibodies, Radiographic Findings","Traditional Chinese Medicine",50
"NCT04305106","https://ClinicalTrials.gov/show/NCT04305106",NA,"China","Shandong","2020-Mar","Recruiting","Randomized","Triple",2,"Confirmed","Severe",NA,"Clinical Improvement Score (Any)","Bevacizumab",140
"NCT04323514","https://ClinicalTrials.gov/show/NCT04323514",NA,"Italy","Palermo","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, Peak RRadiographic Findings","Nutritional Support",500
"CHICTR2000031271","http://www.chictr.org.cn/showproj.aspx?proj=51194",NA,"China","Guangdong","2020-Mar","Not Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"Mortality, ICU Admission, Hospitalization, Organ Failure or Dysfunction (SOFA), Quality of Life","Amino acid",80
"CHICTR2000030028","http://www.chictr.org.cn/showproj.aspx?proj=49840",NA,"China","Sichuan","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Severe",NA,"PD-1, Monocyte Count, Lymphocyte Count, Natural Killer Cell Count, Dendritic Cell Count, Neutrophils, CD4, CD8","Pd-1 Antibodies",40
"CHICTR2000030936","http://www.chictr.org.cn/showproj.aspx?proj=51100",NA,"China","Sichuan","2020-Mar","Recruiting","Non-Randomized","Unspecified",2,"Confirmed Or Suspected",NA,"Mixed","Fever","Traditional Chinese Medicine",2840
"CHICTR2000031139","http://www.chictr.org.cn/showproj.aspx?proj=51404",NA,"China","Hubei","2020-Mar","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,NA,"Pneumonia or ARDS, Blood Gas, Radiographic Findings, Quality of Life, Depression, Anxiety, Distress","Cell product",20
"CHICTR2000031138","http://www.chictr.org.cn/showproj.aspx?proj=51416",NA,"China","Hunan","2020-Mar","Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"Clinical Improvement Score (Any), Pneumonia or ARDS, Blood Gas, PaO2-FiO2, SpO2, Respiratory Rate","Pirfenidone",40
"CHICTR2000030988","http://www.chictr.org.cn/showproj.aspx?proj=51317",NA,"China","Guangdong","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Hospitalization, Hospital Discharge, Pneumonia or ARDS, Treatment-emergent Adverse Events","Traditional Chinese Medicine",204
"CHICTR2000030937","http://www.chictr.org.cn/showproj.aspx?proj=51240",NA,"China","Guangdong","2020-Mar","Recruiting","Randomized","Open-Label",2,"Resolved",NA,"Discharged","Other Mild Symptoms","Traditional Chinese Medicine",144
"CHICTR2000030940","http://www.chictr.org.cn/showproj.aspx?proj=51061",NA,"China","Shanghai","2020-Mar","Not Recruiting","Non-Randomized","Unspecified",2,"Confirmed","Non-severe",NA,"Clinical Improvement Score (Any), Pneumonia or ARDS, Cough, Fever, Dyspnea","Traditional Chinese Medicine",76
"CHICTR2000030923","http://www.chictr.org.cn/showproj.aspx?proj=51139",NA,"China","Shaanxi","2020-Mar","Recruiting","Randomized","Open-Label",4,"Confirmed Or Suspected",NA,NA,"Clinical Improvement Score (Any), Viral Load or Clearance","Traditional Chinese Medicine",400
"CHICTR2000030920","http://www.chictr.org.cn/showproj.aspx?proj=50476",NA,"China","Zhejiang","2020-Mar","Recruiting","Randomized","Unspecified",4,"Resolved",NA,"Discharged","Viral Load or Clearance, Secondary CoViD-19 Re-infection, C-Reactive Protein, IL-2, IL-4, IL-6, IL-10, Tumor Necrosis Factor (Any), Lymphocyte Count, Weight, Height or BMI, Albumin, IgG, IgM or IgA, Antibodies, CD4, CD8","Traditional Chinese Medicine",100
"CHICTR2000031090","http://www.chictr.org.cn/showproj.aspx?proj=51148",NA,"China","Zhejiang","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Quality of Life, Depression, Anxiety, Distress","Psychological",60
"CHICTR2000031089","http://www.chictr.org.cn/showproj.aspx?proj=51136",NA,"China","Guangdong","2020-Mar","Not Recruiting","Non-Randomized","Unspecified",2,"Confirmed","Mixed",NA,"Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, White Blood Cell Count, Platelet Count, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, ALT, AST, Albumin, Bilirubin, Radiographic Findings","Traditional Chinese Medicine",300
"CHICTR2000030420","http://www.chictr.org.cn/showproj.aspx?proj=50286",NA,"China","Liaoning","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected",NA,NA,"Depression, Anxiety, Distress","Traditional Chinese Medicine",60
"CHICTR2000030539","http://www.chictr.org.cn/showproj.aspx?proj=50660",NA,"China","Guangdong","2020-Mar","Not Recruiting","Non-Randomized","Unspecified",2,"Confirmed","Non-severe","Outpatients","Viral Load or Clearance","Hydrogen Peroxide",40
"CHICTR2000030946","http://www.chictr.org.cn/showproj.aspx?proj=51265",NA,"China","Guangdong","2020-Mar","Recruiting","Non-Randomized","Unspecified",2,"Confirmed",NA,"Hospitalized",NA,"LMW Heparin",120
"CHICTR2000030933","http://www.chictr.org.cn/showproj.aspx?proj=51184",NA,"China","Jiangxi","2020-Mar","Not Recruiting","Randomized","Open-Label",3,"Resolved",NA,"Discharged","Fever, Respiratory Rate, 6-Minute Walking Distance, Quality of Life, Depression, Anxiety, Distress","Traditional Chinese Medicine",108
"NCT04291053","https://ClinicalTrials.gov/show/NCT04291053",NA,"China","Beijing","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe","Outpatients","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, PaO2-FiO2, SpO2, Respiratory Rate","Traditional Chinese Medicine",550
"NCT04304313","https://ClinicalTrials.gov/show/NCT04304313",NA,"China","Hubei","2020-Mar","Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed",NA,"Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Organ Failure or Dysfunction (SOFA), Adverse Events, C-Reactive Protein, CK-MB, ALT, PaO2-FiO2, SpO2, Radiographic Findings","Sildenafil",10
"NCT04278963","https://ClinicalTrials.gov/show/NCT04278963",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Double",4,"Confirmed","Mixed","Hospitalized","Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, PaO2-FiO2, SpO2, Respiratory Rate","Traditional Chinese Medicine",300
"NCT04310865","https://ClinicalTrials.gov/show/NCT04310865",NA,"China","Hubei","2020-Mar","Not Recruiting","Randomized","Quadruple",3,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Lymphocyte Count, PaO2-FiO2, SpO2","Traditional Chinese Medicine",116
"NCT04261270","https://ClinicalTrials.gov/show/NCT04261270",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Single",3,"Confirmed","Mixed","Hospitalized","ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, Adverse Events, C-Reactive Protein, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, ALT, PaO2-FiO2, SpO2, Respiratory Rate","Combination Antiviral",60
"NCT04263402","https://ClinicalTrials.gov/show/NCT04263402",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Single",2,"Confirmed","Severe",NA,"ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), PaO2-FiO2, SpO2, Radiographic Findings","Corticosteroid(s)",100
"CHICTR2000029869","http://www.chictr.org.cn/showproj.aspx?proj=49486",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Non-severe",NA,"Mortality, ICU Admission, Pneumonia or ARDS, C-Reactive Protein, Tumor Necrosis Factor (Any), Interferon (Any), Creatinine Phosphokinase, CK-MB, eGFR, ALT, AST, Albumin, Bilirubin, SpO2, Radiographic Findings","Traditional Chinese Medicine",300
"CHICTR2000029978","http://www.chictr.org.cn/showproj.aspx?proj=49702",NA,"China","Shanghai","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed","Hospitalized","Hospitalization, Cough, Fever, Dyspnea, PD-1, Weight, Height or BMI, Creatinine Phosphokinase, CK-MB, ALT, AST, CD4, CD8, Respiratory Rate, Radiographic Findings, Depression, Anxiety, Distress","Traditional Chinese Medicine",186
"CHICTR2000029956","http://www.chictr.org.cn/showproj.aspx?proj=49618",NA,"China","Sichuan","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Resolved",NA,"Discharged","Cough, Fever, Dyspnea, Other Mild Symptoms, Quality of Life, Depression, Anxiety, Distress","Traditional Chinese Medicine",120
"CHICTR2000029658","http://www.chictr.org.cn/showproj.aspx?proj=49074",NA,"China","Hubei","2020-Feb","Status Unclear","Randomized","Unspecified",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, SpO2, Hypoxia","Oxygen",60
"CHICTR2000030469","http://www.chictr.org.cn/showproj.aspx?proj=50082",NA,"China","Shanghai","2020-Mar","Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed","Hospitalized","Hospitalization, Pneumonia or ARDS, Fever, SpO2, Radiographic Findings","Traditional Chinese Medicine",96
"CHICTR2000030188","http://www.chictr.org.cn/showproj.aspx?proj=50025",NA,"China","Guangdong","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed","Severe",NA,"Mortality, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Erythrocyte Sedimentation Rate, Blood Gas","Traditional Chinese Medicine",120
"NCT04308317","https://ClinicalTrials.gov/show/NCT04308317",NA,"China","Zhejiang","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed",NA,"Mortality, Fever","Tetrandrine",60
"CHICTR2000030804","http://www.chictr.org.cn/showproj.aspx?proj=51018",NA,"China","Guangdong","2020-Mar","Recruiting","Randomized","Unspecified",2,"Confirmed","Non-severe",NA,"Hospitalization, Cough, C-Reactive Protein","Traditional Chinese Medicine",128
"CHICTR2000030896","http://www.chictr.org.cn/showproj.aspx?proj=51028",NA,"China","Henan","2020-Mar","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Non-severe",NA,"Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings","Traditional Chinese Medicine",24
"CHICTR2000030892","http://www.chictr.org.cn/showproj.aspx?proj=51118",NA,"China","Guangdong","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Hospitalization, Hospital Discharge, Treatment-emergent Adverse Events, Radiographic Findings","Pirfenidone",40
"CHICTR2000030897","http://www.chictr.org.cn/showproj.aspx?proj=50462",NA,"China","Zhejiang","2020-Mar","Recruiting","Randomized","Unspecified",2,"Resolved",NA,"Discharged","Hospitalization, Hospital Discharge, Viral Load or Clearance, Fever, C-Reactive Protein, IL-2, IL-4, IL-6, IL-8, IL-10, Tumor Necrosis Factor (Any), Interferon (Any), White Blood Cell Count, Monocyte Count, Weight, Height or BMI, Albumin, IgG, IgM or IgA, Antibodies, CD4, Radiographic Findings","Traditional Chinese Medicine",20
"CHICTR2000030855","http://www.chictr.org.cn/showproj.aspx?proj=51090",NA,"China","Guizhou","2020-Mar","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Severe","Hospitalized","ICU Admission, Blood Gas, PaO2-FiO2, SpO2, Respiratory Rate","Mechanical Support",200
"CHICTR2000030479","http://www.chictr.org.cn/showproj.aspx?proj=50450",NA,"China","Jiangsu","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Viral Load or Clearance, Pneumonia or ARDS, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, White Blood Cell Count, Lymphocyte Count, Erythrocyte Sedimentation Rate, Procalcitonin, SpO2","Traditional Chinese Medicine",100
"CHICTR2000030864","http://www.chictr.org.cn/showproj.aspx?proj=50662",NA,"China","Hubei","2020-Mar","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,NA,"Viral Load or Clearance, Pneumonia or ARDS, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Natural Killer Cell Count, Creatinine Phosphokinase, CK-MB, eGFR, ALT, AST, Albumin, Bilirubin, Glucose, Radiographic Findings","Traditional Chinese Medicine",50
"CHICTR2000030810","http://www.chictr.org.cn/showproj.aspx?proj=50986",NA,"China","Hubei","2020-Mar","Recruiting","Non-Randomized","Unspecified",2,"Confirmed","Non-severe",NA,"Hospital Discharge, Creatinine Phosphokinase, CK-MB, ALT, AST, Blood Urea Nitrogen","Traditional Chinese Medicine",100
"CHICTR2000030853","http://www.chictr.org.cn/showproj.aspx?proj=51081",NA,"China","Guizhou","2020-Mar","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Severe",NA,"CK-MB, LDH","Dexmedetomidine",200
"CHICTR2000030836","http://www.chictr.org.cn/showproj.aspx?proj=51054",NA,"China","Shanghai","2020-Mar","Not Recruiting","Non-Randomized","Unspecified",2,"Confirmed",NA,NA,"Mortality, ICU Admission, Clinical Improvement Score (Any), Pneumonia or ARDS, Dyspnea, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, Interferon (Any), eGFR, Coagulation Test, ALT, AST, Albumin, Bilirubin, PaO2-FiO2, SpO2, Respiratory Rate","Traditional Chinese Medicine",300
"CHICTR2000030703","http://www.chictr.org.cn/showproj.aspx?proj=50251",NA,"China","Hunan","2020-Mar","Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed",NA,"Blood Gas, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings","Ixekizumab ,  Antiviral",40
"CHICTR2000030545","http://www.chictr.org.cn/showproj.aspx?proj=50126",NA,"China","Hubei","2020-Mar","Recruiting","Randomized","Unspecified",3,"Confirmed",NA,NA,"ICU Admission, Hospitalization, Pneumonia or ARDS, Cough, Fever, Dyspnea, Other Mild Symptoms, Radiographic Findings","Traditional Chinese Medicine",300
"CHICTR2000029991","http://www.chictr.org.cn/showproj.aspx?proj=49666",NA,"China","Jiangxi","2020-Feb","Recruiting","Randomized","Open-Label",3,"Confirmed","Mixed",NA,"Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever","Traditional Chinese Medicine",72
"CHICTR2000030759","http://www.chictr.org.cn/showproj.aspx?proj=49284",NA,"China","Zhejiang","2020-Mar","Not Recruiting","Randomized","Unspecified",2,"Confirmed",NA,"Hospitalized","Viral Load or Clearance, Pneumonia or ARDS, Fever, C-Reactive Protein, IL-1, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-17, Tumor Necrosis Factor (Any), Interferon (Any), Lymphocyte Count, Myoglobin, Troponin, Procalcitonin, Prothrombin, Coagulation Test, Triglycerides, ALT, AST, Albumin, Bilirubin, Glucose, Urine Sample, Blood Gas, Radiographic Findings","Traditional Chinese Medicine",70
"CHICTR2000030849","http://www.chictr.org.cn/showproj.aspx?proj=51086",NA,"China","Henan","2020-Mar","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,NA,"Depression, Anxiety","Psychological",81
"CHICTR2000030388","http://www.chictr.org.cn/showproj.aspx?proj=50306",NA,"China","Hubei","2020-Mar","Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Treatment-emergent Adverse Events, C-Reactive Protein, IL-6, IL-8, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Shock","Traditional Chinese Medicine",60
"CHICTR2000030773","http://www.chictr.org.cn/showproj.aspx?proj=50934",NA,"China","Shanghai","2020-Mar","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"ICU","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Blood purification",20
"CHICTR2000030779","http://www.chictr.org.cn/showproj.aspx?proj=50973",NA,"China","Shanghai","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe",NA,"Mortality, Hospitalization, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), Serious Adverse Events, Blood Gas","Statin",100
"CHICTR2000030761","http://www.chictr.org.cn/showproj.aspx?proj=50956",NA,"China","Shanghai","2020-Mar","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed","Severe",NA,"C-Reactive Protein, IL-6, IL-8, Tumor Necrosis Factor (Any)","Renal Replacement Therapy",20
"CHICTR2000030751","http://www.chictr.org.cn/showproj.aspx?proj=50941",NA,"China","Inner Mongol","2020-Mar","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,NA,"Viral Load or Clearance, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Natural Killer Cell Count, Neutrophils, Platelet Count, Creatinine Phosphokinase, CK-MB, eGFR, ALT, AST, Albumin, Bilirubin, Urine Sample, Blood Gas, Radiographic Findings","Traditional Chinese Medicine",60
"CHICTR2000030744","http://www.chictr.org.cn/showproj.aspx?proj=50910",NA,"China","Shandong","2020-Mar","Recruiting","Non-Randomized","Unspecified",2,"Confirmed","Severe",NA,"Mortality, ICU Admission, Hospitalization","ECMO",30
"CHICTR2000030720","http://www.chictr.org.cn/showproj.aspx?proj=50793",NA,"China","Hubei","2020-Mar","Recruiting","Randomized","Unspecified",2,"Recovering",NA,"Resolved","Clinical Improvement Score (Any), Fever, Antibodies, Radiographic Findings","Traditional Chinese Medicine",120
"NCT04264533","https://ClinicalTrials.gov/show/NCT04264533",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Triple",2,"Confirmed","Severe","ICU","Mortality, ICU Admission, Clinical Improvement Score (Any), PaO2-FiO2, SpO2, Respiratory Rate, Hypoxia, Hypoxemia","Vitamin C",140
"CHICTR2000030700","http://www.chictr.org.cn/showproj.aspx?proj=50786",NA,"China","Hubei","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, SpO2, Respiratory Rate","Enoxaparin Sodium",60
"CHICTR2000030701","http://www.chictr.org.cn/showproj.aspx?proj=50795",NA,"China","Guangdong","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, SpO2, Respiratory Rate","Enoxaparin Sodium",60
"CHICTR2000029479","http://www.chictr.org.cn/showproj.aspx?proj=48773",NA,"China","Sichuan","2020-Feb","Recruiting","Randomized","Open-Label",2,"Healthy","None","Healthy","Pneumonia or ARDS","Traditional Chinese Medicine",20000
"CHICTR2000029550","http://www.chictr.org.cn/showproj.aspx?proj=48775",NA,"China","Sichuan","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"C-Reactive Protein, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Natural Killer Cell Count, Erythrocyte Sedimentation Rate, D-Dimer, Weight, Height or BMI, Creatinine Phosphokinase, Troponin, Procalcitonin, Radiographic Findings","Traditional Chinese Medicine",300
"CHICTR2000029549","http://www.chictr.org.cn/showproj.aspx?proj=49014",NA,"China","Sichuan","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed Or Suspected",NA,NA,"Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, PaO2-FiO2, Radiographic Findings","Traditional Chinese Medicine",400
"CHICTR2000030471","http://www.chictr.org.cn/showproj.aspx?proj=50421",NA,"China","Guangdong","2020-Mar","Recruiting","Randomized","Single",2,"Confirmed","Mixed","Hospitalized Or Outpatients","Mortality, Hospitalization, Clinical Improvement Score (Any), C-Reactive Protein, Erythrocyte Sedimentation Rate","Lipoic Acid",394
"CHICTR2000030578","http://www.chictr.org.cn/showproj.aspx?proj=50690",NA,"China","Shandong","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized","Quality of Life","Exercise",40
"CHICTR2000030540","http://www.chictr.org.cn/showproj.aspx?proj=50658",NA,"China","Hubei","2020-Mar","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","ICU","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, C-Reactive Protein, Erythrocyte Sedimentation Rate, SpO2, Radiographic Findings","Renal Replacement Therapy",152
"CHICTR2000030522","http://www.chictr.org.cn/showproj.aspx?proj=44213",NA,"China","Sichuan","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Mixed","Hospitalized","Clinical Improvement Score (Any), Viral Load or Clearance, Fever, C-Reactive Protein, White Blood Cell Count, Lymphocyte Count, Erythrocyte Sedimentation Rate, Radiographic Findings","Traditional Chinese Medicine",100
"NCT04296643","https://ClinicalTrials.gov/show/NCT04296643",NA,"China","Beijing","2020-Mar","Not Recruiting","Randomized","Single",2,"Healthy (Exposed)","None","Healthcare Workers","Mortality, ICU Admission, Viral Load or Clearance, Labor Absenteeism, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO","Mask",576
"CHICTR2000030518","http://www.chictr.org.cn/showproj.aspx?proj=50586",NA,"China","Zhejiang","2020-Mar","Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed",NA,"Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, IL-2, IL-4, IL-6, IL-10, IL-17, Tumor Necrosis Factor (Any), Interferon (Any), CD4, CD8, Radiographic Findings","Traditional Chinese Medicine",60
"CHICTR2000030490","http://www.chictr.org.cn/showproj.aspx?proj=50487",NA,"China","Hubei","2020-Mar","Recruiting","Single-Arm","Unspecified",1,"Confirmed Or Suspected","Severe",NA,"Viral Load or Clearance","Traditional Chinese Medicine",100
"CHICTR2000030475","http://www.chictr.org.cn/showproj.aspx?proj=50452",NA,"China","Beijing","2020-Mar","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, IL-6, IL-10, Tumor Necrosis Factor (Any)","Membrane Removal",19
"CHICTR2000030472","http://www.chictr.org.cn/showproj.aspx?proj=49753",NA,"China","Liaoning","2020-Mar","Recruiting","Non-Randomized","Unspecified",2,"Confirmed","Mixed","Hospitalized","Viral Load or Clearance, Adverse Events, Serious Adverse Events, PaO2-FiO2, SpO2, Respiratory Rate","Traditional Chinese Medicine",20
"CHICTR2000030477","http://www.chictr.org.cn/showproj.aspx?proj=50458",NA,"China","Beijing","2020-Mar","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO, Fever, Adverse Events, Serious Adverse Events, IL-6, IL-10, Tumor Necrosis Factor (Any)","Oxiris Membrane",19
"CHICTR2000030433","http://www.chictr.org.cn/showproj.aspx?proj=50273",NA,"China","Fujian","2020-Mar","Not Recruiting","Single-Arm","Unspecified",1,"Recovered",NA,"Discharged","Quality of Life","Exercise",80
"CHICTR2000030418","http://www.chictr.org.cn/showproj.aspx?proj=50341",NA,"China","Fujian","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"IL-6, Quality of Life, Distress","Physical rehabiliation",80
"CHICTR2000030481","http://www.chictr.org.cn/showproj.aspx?proj=50453",NA,"China","Hubei","2020-Mar","Recruiting","Randomized","Unspecified",3,"Confirmed",NA,"Hospitalized Or Outpatients","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Organ Failure or Dysfunction (SOFA), Treatment-emergent Adverse Events, Radiographic Findings, Renal Outcome (Unspecified)","Corticosteroid(s)",200
"CHICTR2000030467","http://www.chictr.org.cn/showproj.aspx?proj=50378",NA,"China","Liaoning","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected",NA,NA,"Quality of Life","Traditional Chinese Medicine",60
"CHICTR2000029755","http://www.chictr.org.cn/showproj.aspx?proj=49301",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Clinical Improvement Score (Any)","Traditional Chinese Medicine",120
"CHICTR2000030398","http://www.chictr.org.cn/showproj.aspx?proj=50173",NA,"China","Hubei","2020-Mar","Not Recruiting","Randomized","Double",2,"Confirmed",NA,"Hospitalized","Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance","Bismuth Potassium Citrate",340
"CHICTR2000030432","http://www.chictr.org.cn/showproj.aspx?proj=50268",NA,"China","Fujian","2020-Mar","Not Recruiting","Randomized","Open-Label",2,"Healthy (Exposed)","None","Healthcare Workers","Quality of Life","Exercise",80
"CHICTR2000030022","http://www.chictr.org.cn/showproj.aspx?proj=49797",NA,"China","Anhui","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Clinical Improvement Score (Any), Viral Load or Clearance, Lung Inflamation","Traditional Chinese Medicine",100
"CHICTR2000030386","http://www.chictr.org.cn/showproj.aspx?proj=50323",NA,"China","Hunan","2020-Feb","Not Recruiting","Single-Arm","Unspecified",1,"Healthy (Exposed Or Unexposed)","None","Post Exposure Prophylaxis","Quality of Life","Traditional Chinese Medicine",1000
"CHICTR2000030219","http://www.chictr.org.cn/showproj.aspx?proj=50110",NA,"China","Tianjin","2020-Feb","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,NA,"Viral Load or Clearance, C-Reactive Protein, Radiographic Findings","Traditional Chinese Medicine",120
"CHICTR2000030333","http://www.chictr.org.cn/showproj.aspx?proj=48801",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe",NA,"Mortality, Viral Load or Clearance, Cough, Dyspnea, IL-8, Lymphocyte Count, Blood Gas","Pirfenidone",292
"CHICTR2000030324","http://www.chictr.org.cn/showproj.aspx?proj=50231",NA,"China","Hubei","2020-Feb","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,NA,"Cough, Fever, Dyspnea","Traditional Chinese Medicine",40
"CHICTR2000030007","http://www.chictr.org.cn/showproj.aspx?proj=49619",NA,"China","Guangdong","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed",NA,"Viral Load or Clearance, Radiographic Findings","G-Csf",200
"CHICTR2000030314","http://www.chictr.org.cn/showproj.aspx?proj=50248",NA,"China","Hubei","2020-Feb","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,NA,"Cough, Fever, Dyspnea","Traditional Chinese Medicine",40
"CHICTR2000030288","http://www.chictr.org.cn/showproj.aspx?proj=50202",NA,"China","Beijing","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Clinical Improvement Score (Any), Viral Load or Clearance","Traditional Chinese Medicine",204
"CHICTR2000030265","http://www.chictr.org.cn/showproj.aspx?proj=49691",NA,"China","Heilongjiang","2020-Feb","Not Recruiting","Randomized","Unspecified",3,"Confirmed","Severe","Hospitalized","Mortality, Clinical Improvement Score (Any), Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Lymphocyte Count","Renal Replacement Therapy",30
"NCT04285190","https://ClinicalTrials.gov/show/NCT04285190",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe",NA,"Mortality, Hospitalization, Fever, Dyspnea, Other Mild Symptoms, White Blood Cell Count, Lymphocyte Count, Neutrophils, Platelet Count, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, Troponin, LDH, SpO2","Traditional Chinese Medicine",120
"CHICTR2000030260","http://www.chictr.org.cn/showproj.aspx?proj=50130",NA,"China","Sichuan","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"C-Reactive Protein, IL-6, Tumor Necrosis Factor (Any), White Blood Cell Count, Lymphocyte Count, Albumin","Nutritional Support",20
"CHICTR2000030225","http://www.chictr.org.cn/showproj.aspx?proj=49945",NA,"China","Shanghai","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed",NA,"Hospitalization, Hospital Discharge, Clinical Improvement Score (Any)","Traditional Chinese Medicine",186
"CHICTR2000030262","http://www.chictr.org.cn/showproj.aspx?proj=50136",NA,"China","Shanghai","2020-Feb","Recruiting","Unspecified","Unspecified",3,"Confirmed",NA,NA,"Viral Load or Clearance, Radiographic Findings","Combination Antiviral",30
"CHICTR2000030258","http://www.chictr.org.cn/showproj.aspx?proj=49887",NA,"China","Heilongjiang","2020-Feb","Not Recruiting","Single-Arm","Open-Label",2,"Confirmed",NA,"Hospitalized","Fever, SpO2, Respiratory Rate","Hydrogen inhalation",60
"CHICTR2000030259","http://www.chictr.org.cn/showproj.aspx?proj=49918",NA,"China","Shanghai","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed","Hospitalized","Viral Load or Clearance, PaO2-FiO2, SpO2, Respiratory Rate","Danoprevir ,  Ritonavir",60
"CHICTR2000030261","http://www.chictr.org.cn/showproj.aspx?proj=49963",NA,"China","Jiangsu","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed Or Suspected",NA,NA,"Viral Load or Clearance, White Blood Cell Count, Lymphocyte Count, Radiographic Findings","Inhaled Exosome",26
"CHICTR2000030255","http://www.chictr.org.cn/showproj.aspx?proj=50089",NA,"China","Shanghai","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed",NA,"Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Dyspnea, Other Mild Symptoms, SpO2, Respiratory Rate, Radiographic Findings","Traditional Chinese Medicine",300
"NCT04282902","https://ClinicalTrials.gov/show/NCT04282902",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, PaO2-FiO2, SpO2, Radiographic Findings","Pirfenidone",294
"CHICTR2000030002","http://www.chictr.org.cn/showproj.aspx?proj=49738",NA,"China","Anhui","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed",NA,"Mortality, Hospitalization, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Tranilast",60
"CHICTR2000030165","http://www.chictr.org.cn/showproj.aspx?proj=49947",NA,"China","Tianjin","2020-Feb","Recruiting","Randomized","Unspecified",3,"Confirmed","Mixed",NA,"Viral Load or Clearance, SpO2, Radiographic Findings","Ozone",60
"CHICTR2000030167","http://www.chictr.org.cn/showproj.aspx?proj=49567",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed","Hospitalized","Mortality, Hospitalization, Viral Load or Clearance, C-Reactive Protein, Natural Killer Cell Count, CD4, CD8, SpO2","Interleukin",80
"CHICTR2000029851","http://www.chictr.org.cn/showproj.aspx?proj=49534",NA,"China","Shanghai","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed","Severe",NA,"Mortality, Clinical Improvement Score (Any), Viral Load or Clearance","Alpha Lipoic Acid",68
"CHICTR2000030170","http://www.chictr.org.cn/showproj.aspx?proj=50017",NA,"China","Shanghai","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any)","Jakotinib Hydrochloride",16
"CHICTR2000030102","http://www.chictr.org.cn/showproj.aspx?proj=49747",NA,"China","Tianjin","2020-Feb","Recruiting","Randomized","Unspecified",6,"Confirmed","Mixed",NA,"Viral Load or Clearance, Cough, Fever, Dyspnea, Treatment-emergent Adverse Events, C-Reactive Protein, Blood Gas, SpO2, Radiographic Findings, Renal Outcome (Unspecified), Cardiac Outcome (Unspecified)","Ozone",180
"CHICTR2000030089","http://www.chictr.org.cn/showproj.aspx?proj=49889",NA,"China","Shanghai","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Severe",NA,"Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events","Adalimumab",60
"CHICTR2000030093","http://www.chictr.org.cn/showproj.aspx?proj=49932",NA,"China","Shanxi","2020-Feb","Not Recruiting","Non-Randomized","Unspecified",2,"Healthy (Exposed)",NA,"Healthcare Workers","Anxiety","Emotional Support",60
"CHICTR2000030084","http://www.chictr.org.cn/showproj.aspx?proj=49952",NA,"China","Shanxi","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"Depression, Anxiety","Psychological",180
"CHICTR2000030058","http://www.chictr.org.cn/showproj.aspx?proj=49831",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Double",2,"Confirmed","Mixed",NA,"Viral Load or Clearance, Fever, C-Reactive Protein, Lymphocyte Count, Radiographic Findings","Lenflunomide",200
"NCT04273529","https://ClinicalTrials.gov/show/NCT04273529",NA,"China","Zhejiang","2020-Feb","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Mixed",NA,"Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, MCP-1, PaO2-FiO2, SpO2, Respiratory Rate","Thalidomide",100
"NCT04273581","https://ClinicalTrials.gov/show/NCT04273581",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Quadruple",2,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events, IL-1, IL-2, IL-6, IL-7, IL-8, IL-10, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, IP-10, MCP-1, MIP-1","Thalidomide",40
"NCT04280588","https://ClinicalTrials.gov/show/NCT04280588",NA,"China","Beijing","2020-Feb","Recruiting","Non-Randomized","Open-Label",2,"Confirmed","Mixed",NA,"Pneumonia or ARDS","Fingolimod",30
"NCT04279197","https://ClinicalTrials.gov/show/NCT04279197",NA,"China","Shanghai","2020-Feb","Recruiting","Randomized","Double",2,"Negative(?)",NA,NA,"Pneumonia or ARDS, Dyspnea, 6-Minute Walking Distance, Radiographic Findings","Traditional Chinese Medicine",136
"CHICTR2000030034","http://www.chictr.org.cn/showproj.aspx?proj=49647",NA,"China","Zhejiang","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"Viral Load or Clearance, Pneumonia or ARDS, Fever","Traditional Chinese Medicine",132
"CHICTR2000030033","http://www.chictr.org.cn/showproj.aspx?proj=49703",NA,"China","Guangdong","2020-Feb","Not Recruiting","Randomized","Open-Label",3,"Healthy (Exposed)","None","Healthy (Exposed)","Household Members with CoViD-19","Traditional Chinese Medicine",828
"CHICTR2000030029","http://www.chictr.org.cn/showproj.aspx?proj=49824",NA,"China","Zhejiang","2020-Feb","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,NA,"Mortality, ICU Admission, Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO","Suramin",20
"CHICTR2000030043","http://www.chictr.org.cn/showproj.aspx?proj=49866",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed Or Suspected","Severe",NA,"ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA)","Traditional Chinese Medicine",300
"CHICTR2000030027","http://www.chictr.org.cn/showproj.aspx?proj=49852",NA,"China","Beijing","2020-Feb","Recruiting","Single-Arm","Unspecified",1,"Confirmed","Severe",NA,"Clinical Improvement Score (Any)","Traditional Chinese Medicine",60
"CHICTR2000030016","http://www.chictr.org.cn/showproj.aspx?proj=49799",NA,"China","Guangxi","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed",NA,NA,"Mortality, Clinical Improvement Score (Any), Viral Load or Clearance, Serious or Seconday Infections, Organ Failure or Dysfunction (SOFA), Adverse Events","Inhaled solution",60
"NCT04275245","https://ClinicalTrials.gov/show/NCT04275245","https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1.full.pdf","China","Shaanxi","2020-Feb","Completed w. Results","Single-Arm","Open-Label",1,"Confirmed",NA,NA,"Viral Load or Clearance, Pneumonia or ARDS, Fever, C-Reactive Protein, D-Dimer, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings","Mepaluzumab",20
"CHICTR2000029994","http://www.chictr.org.cn/showproj.aspx?proj=49309",NA,"China","Shanghai","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Severe",NA,"Hospitalization, Lymphocyte Count, Natural Killer Cell Count, Radiographic Findings, Renal Outcome (Unspecified)","Traditional Chinese Medicine",200
"CHICTR2000030006","http://www.chictr.org.cn/showproj.aspx?proj=49737",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed",NA,"Hospitalized","Mortality, Viral Load or Clearance, Fever, Radiographic Findings, Lung Inflamation","Ozone",60
"CHICTR2000029999","http://www.chictr.org.cn/showproj.aspx?proj=49717",NA,"China","Shanghai","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed",NA,"Fever, C-Reactive Protein, IL-2, IL-4, IL-6, IL-10, IL-12, Tumor Necrosis Factor (Any), Interferon (Any), Erythrocyte Sedimentation Rate, D-Dimer, Weight, Height or BMI, ALT, AST, Albumin, IgG, IgM or IgA, Blood Pressure, ECG, Respiratory Rate, Radiographic Findings","Probiotics",60
"CHICTR2000030000","http://www.chictr.org.cn/showproj.aspx?proj=49748",NA,"China","Jiangxi","2020-Feb","Recruiting","Non-Randomized","Unspecified",5,"Confirmed",NA,"Hospitalized","Viral Load or Clearance, Adverse Events, PaO2-FiO2, SpO2, Respiratory Rate","Traditional Chinese Medicine",50
"CHICTR2000030001","http://www.chictr.org.cn/showproj.aspx?proj=49723",NA,"China","Heilongjiang","2020-Feb","Recruiting","Randomized","Double",2,"Confirmed",NA,"Hospitalized","Mortality, Viral Load or Clearance, Fever, Radiographic Findings, Lung Inflamation","Triazavirin",240
"CHICTR2000030003","http://www.chictr.org.cn/showproj.aspx?proj=49770",NA,"China","Sichuan","2020-Feb","Not Recruiting","Randomized","Unspecified",3,"Confirmed","Non-severe",NA,"Hospitalization, Hospital Discharge, Fever","Traditional Chinese Medicine",480
"CHICTR2000029855","http://www.chictr.org.cn/showproj.aspx?proj=49543",NA,"China","Zhejiang","2020-Feb","Recruiting","Randomized","Unspecified",3,"Confirmed","Non-severe",NA,"Clinical Improvement Score (Any), Viral Load or Clearance, Fever","Traditional Chinese Medicine",180
"CHICTR2000029974","http://www.chictr.org.cn/showproj.aspx?proj=49321",NA,"China","Shandong","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Outpatients And Hospitalized","Mortality, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Serious or Seconday Infections, Radiographic Findings","Probiotics",300
"CHICTR2000029780","http://www.chictr.org.cn/showproj.aspx?proj=49220",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe","Outpatients","Viral Load or Clearance, Dyspnea, Other Mild Symptoms, Adverse Events, Serious Adverse Events","Traditional Chinese Medicine",160
"CHICTR2000029781","http://www.chictr.org.cn/showproj.aspx?proj=49138",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Fever","Traditional Chinese Medicine",160
"CHICTR2000029941","http://www.chictr.org.cn/showproj.aspx?proj=49596",NA,"China","Shanghai","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed And Suspected","Mixed",NA,"Hospitalization, Viral Load or Clearance, Fever, Adverse Events, Serious Adverse Events, Radiographic Findings","Traditional Chinese Medicine",200
"CHICTR2000029960","http://www.chictr.org.cn/showproj.aspx?proj=49639",NA,"China","Hunan","2020-Feb","Not Recruiting","Non-Randomized","Unspecified",2,"Confirmed Or Suspected",NA,NA,NA,"Traditional Chinese Medicine",100
"CHICTR2000029972","http://www.chictr.org.cn/showproj.aspx?proj=49664",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"Viral Load or Clearance","Electrotherapy",40
"CHICTR2000029742","http://www.chictr.org.cn/showproj.aspx?proj=49297",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Unspecified",5,"Confirmed Or Suspected","Mixed",NA,"Viral Load or Clearance, Radiographic Findings","Traditional Chinese Medicine",90
"CHICTR2000029954","http://www.chictr.org.cn/showproj.aspx?proj=49402",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Open-Label",3,"Confirmed","Mixed","Outpatients And Hospitalized","ICU Admission, Viral Load or Clearance, Pneumonia or ARDS, Cough, Fever, Other Mild Symptoms, Radiographic Findings","Traditional Chinese Medicine",300
"CHICTR2000029947","http://www.chictr.org.cn/showproj.aspx?proj=49599",NA,"China","Shanghai","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","Hospitalized","Viral Load or Clearance, Serious or Seconday Infections, Adverse Events, Quality of Life","Traditional Chinese Medicine",200
"CHICTR2000029789","http://www.chictr.org.cn/showproj.aspx?proj=49348",NA,"China","Henan","2020-Feb","Recruiting","Randomized","Unspecified",2,"Resolved","Mixed","Discharged","Visits or Returns to Emergency Department, Pneumonia or ARDS, Radiographic Findings, Quality of Life","Traditional Chinese Medicine",100
"CHICTR2000029849","http://www.chictr.org.cn/showproj.aspx?proj=49530",NA,"China","Henan","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed","Severe",NA,"Mortality, Hospitalization, Pneumonia or ARDS, Fever","Regulating Intestinal Flora Agent",60
"CHICTR2000029763","http://www.chictr.org.cn/showproj.aspx?proj=49408",NA,"China","Beijing","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized","Fever, Radiographic Findings, Quality of Life","Traditional Chinese Medicine",408
"CHICTR2000029769","http://www.chictr.org.cn/showproj.aspx?proj=49415",NA,"China","Zhejiang","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","Hospitalized","Mortality","Traditional Chinese Medicine",40
"CHICTR2000029819","http://www.chictr.org.cn/showproj.aspx?proj=49490",NA,"China","Zhejiang","2020-Feb","Recruiting","Non-Randomized","Unspecified",2,"Confirmed","Severe",NA,"Viral Load or Clearance, Radiographic Findings","Traditional Chinese Medicine",80
"CHICTR2000029813","http://www.chictr.org.cn/showproj.aspx?proj=49425",NA,"China","Shanghai","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Viral Load or Clearance, Cough, Fever, C-Reactive Protein, SpO2","Traditional Chinese Medicine",72
"CHICTR2000029790","http://www.chictr.org.cn/showproj.aspx?proj=49453",NA,"China","Shanghai","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"Hospitalization, Viral Load or Clearance, Fever","Traditional Chinese Medicine",120
"CHICTR2000029814","http://www.chictr.org.cn/showproj.aspx?proj=49387",NA,"China","Shanghai","2020-Feb","Recruiting","Non-Randomized","Unspecified",2,"Confirmed",NA,NA,"Viral Load or Clearance, Cough, Fever, Dyspnea","Traditional Chinese Medicine",30
"CHICTR2000029822","http://www.chictr.org.cn/showproj.aspx?proj=49502",NA,"China","Hebei","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Hospitalization, Viral Load or Clearance, Fever, Respiratory Rate","Honeysuckle",110
"CHICTR2000029806","http://www.chictr.org.cn/showproj.aspx?proj=49161",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Unspecified",3,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any)","Thymosin",120
"NCT04268537","https://ClinicalTrials.gov/show/NCT04268537",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Single",3,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, IL-6, Lymphocyte Count, Procalcitonin, Radiographic Findings","Pd1 Blocking, Thymosin",120
"CHICTR2000029788","http://www.chictr.org.cn/showproj.aspx?proj=49452",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Non-severe",NA,"Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Blood Gas","Traditional Chinese Medicine",60
"CHICTR2000029778","http://www.chictr.org.cn/showproj.aspx?proj=49422",NA,"China","Shanghai","2020-Feb","Recruiting","Non-Randomized","Unspecified",4,"Confirmed",NA,NA,"Hospitalization, Viral Load or Clearance, Fever, Blood Gas","Traditional Chinese Medicine",600
"CHICTR2000029776","http://www.chictr.org.cn/showproj.aspx?proj=49342",NA,"China","Zhejiang","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed","Non-severe",NA,"ICU Admission, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms","Polyinosinic- Polycytidylic Acid",40
"CHICTR2000029768","http://www.chictr.org.cn/showproj.aspx?proj=49131",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,"Hospitalized","Hospitalization, Hospital Discharge, Viral Load or Clearance","Traditional Chinese Medicine",60
"CHICTR2000029777","http://www.chictr.org.cn/showproj.aspx?proj=49380",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","Hospitalized","Mortality, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Coagulation Test, SpO2, Radiographic Findings","Traditional Chinese Medicine",160
"CHICTR2000029747","http://www.chictr.org.cn/showproj.aspx?proj=49287",NA,"China","Anhui","2020-Feb","Recruiting","Randomized","Open-Label",2,"Confirmed",NA,NA,"Radiographic Findings","Traditional Chinese Medicine",200
"CHICTR2000029518","http://www.chictr.org.cn/showproj.aspx?proj=48860",NA,"China","Zhejiang","2020-Feb","Recruiting","Randomized","Double",4,"Confirmed","Mixed",NA,"Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Fever, Other Mild Symptoms, Adverse Events, Serious Adverse Events, Quality of Life","Traditional Chinese Medicine",140
"CHICTR2000029517","http://www.chictr.org.cn/showproj.aspx?proj=48861",NA,"China","Zhejiang","2020-Feb","Recruiting","Randomized","Double",2,"Suspected",NA,NA,"Mortality, Pneumonia or ARDS","Traditional Chinese Medicine",100
"CHICTR2000029602","http://www.chictr.org.cn/showproj.aspx?proj=48985",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Open-Label",2,"Healthy (Exposed)",NA,"Healthy (Exposed)","Clinical Improvement Score (Any), Viral Load or Clearance, Fever","Traditional Chinese Medicine",600
"CHICTR2000029601","http://www.chictr.org.cn/showproj.aspx?proj=48988",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed Or Suspected",NA,NA,"Clinical Improvement Score (Any), Viral Load or Clearance, Fever","Traditional Chinese Medicine",400
"CHICTR2000029589","http://www.chictr.org.cn/showproj.aspx?proj=49104",NA,"China","Beijing","2020-Feb","Recruiting","Non-Randomized","Open-Label",2,"Confirmed",NA,NA,"Viral Load or Clearance, Cough, Fever, Dyspnea, Blood Gas","Traditional Chinese Medicine",60
"CHICTR2000029578","http://www.chictr.org.cn/showproj.aspx?proj=49080",NA,"China","Zhejiang","2020-Feb","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,NA,"Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Cough, Fever, Other Mild Symptoms, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Traditional Chinese Medicine",1000
"CHICTR2000029636","http://www.chictr.org.cn/showproj.aspx?proj=49215",NA,"China","Hubei","2020-Feb","Recruiting","Single-Arm","Unspecified",1,"Confirmed",NA,"Hospitalized","Viral Load or Clearance, Cough, Fever, Other Mild Symptoms","vMIP",40
"CHICTR2000029739","http://www.chictr.org.cn/showproj.aspx?proj=49283",NA,"China","Guangdong","2020-Feb","Recruiting","Randomized","Unspecified",2,"Confirmed","Mixed","Hospitalized","ICU Admission, Hospital Discharge, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Cough, Fever, Dyspnea, Other Mild Symptoms, C-Reactive Protein, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, ALT, AST, Albumin, Bilirubin, Quality of Life","Oxygen",440
"CHICTR2000029656","http://www.chictr.org.cn/showproj.aspx?proj=49086",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Clinical Improvement Score (Any), ECG, Radiographic Findings","Corticosteroid(s)",100
"CHICTR2000029544","http://www.chictr.org.cn/showproj.aspx?proj=49013",NA,"China","Zhejiang","2020-Feb","Not Recruiting","Randomized","Unspecified",3,"Confirmed",NA,NA,"Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Invasive Mechanical Ventilation or ECMO, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events, ECG","Baloxavir, Marboxil, Favirapir",30
"CHICTR2000029605","http://www.chictr.org.cn/showproj.aspx?proj=49051",NA,"China","Hubei","2020-Feb","Recruiting","Randomized","Open-Label",4,"Confirmed",NA,NA,"ICU Admission, Viral Load or Clearance, Cough, Fever, Other Mild Symptoms","Traditional Chinese Medicine",400
"CHICTR2000029432","http://www.chictr.org.cn/showproj.aspx?proj=48881",NA,"China","Guangdong","2020-Feb","Not Recruiting","Single-Arm","Unspecified",1,"Confirmed Or Suspected","Mixed","Hospitalized","Fever, C-Reactive Protein, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Procalcitonin, ALT, AST, Albumin, Bilirubin, Blood Gas","Traditional Chinese Medicine",72
"CHICTR2000029418","http://www.chictr.org.cn/showproj.aspx?proj=48886",NA,"China","Beijing","2020-Jan","Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","Hospitalized","ICU Admission, Blood Gas, PaO2-FiO2, SpO2, Respiratory Rate","Traditional Chinese Medicine",42
"CHICTR2000029439","http://www.chictr.org.cn/showproj.aspx?proj=48904",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Non-severe","Outpatients","Viral Load or Clearance, Pneumonia or ARDS, Fever, Adverse Events, Serious Adverse Events, PaO2-FiO2, SpO2, Respiratory Rate","Traditional Chinese Medicine",120
"CHICTR2000029438","http://www.chictr.org.cn/showproj.aspx?proj=48911",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Fever, Organ Failure or Dysfunction (SOFA), Deep Vein Thrombosis or Pulmonary Embolism","Traditional Chinese Medicine",100
"CHICTR2000029436","http://www.chictr.org.cn/showproj.aspx?proj=48884",NA,"China","Henan","2020-Feb","Not Recruiting","Non-Randomized","Unspecified",2,"Confirmed",NA,NA,"Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Blood Gas, Radiographic Findings, Quality of Life","Traditional Chinese Medicine",100
"CHICTR2000029435","http://www.chictr.org.cn/showproj.aspx?proj=48827",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Unspecified",8,"Healthy (Exposed) Or Suspected",NA,"Outpatients","Viral Load or Clearance, Fever, Weight, Height or BMI, Creatinine Phosphokinase, CK-MB, eGFR, ALT, AST, Albumin, Bilirubin, Blood Pressure, Heart Rate, Radiographic Findings","Traditional Chinese Medicine",160
"CHICTR2000029431","http://www.chictr.org.cn/showproj.aspx?proj=48907",NA,"China","Liaoning","2020-Feb","Recruiting","Randomized","Unspecified",3,"Confirmed",NA,NA,"Pneumonia or ARDS, Radiographic Findings","M1 Macrophage Suppressor",45
"CHICTR2000029495","http://www.chictr.org.cn/showproj.aspx?proj=48971",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Open-Label",3,"Resolved",NA,"Discharged","Quality of Life, Depression, Anxiety","Traditional Chinese Medicine",90
"CHICTR2000029558","http://www.chictr.org.cn/showproj.aspx?proj=48792",NA,"China","Sichuan","2020-Feb","Recruiting","Single-Arm","Unspecified",1,"Confirmed Or Suspected",NA,NA,"Viral Load or Clearance, C-Reactive Protein, Erythrocyte Sedimentation Rate, D-Dimer, Myoglobin, Troponin, Blood Gas, Radiographic Findings","Traditional Chinese Medicine",200
"CHICTR2000029459","http://www.chictr.org.cn/showproj.aspx?proj=48929",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Resolved",NA,"Discharged","Adverse Events, Serious Adverse Events, PaO2-FiO2, SpO2, Respiratory Rate, 6-Minute Walking Distance, Quality of Life","Pulmonary Rehabilitation",100
"CHICTR2000029460","http://www.chictr.org.cn/showproj.aspx?proj=48930",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Resolved",NA,"Discharged","Adverse Events, 6-Minute Walking Distance, Quality of Life","Shadowboxing",100
"CHICTR2000029461","http://www.chictr.org.cn/showproj.aspx?proj=48927",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Confirmed",NA,NA,"Viral Load or Clearance, Cough, Fever, Adverse Events, 6-Minute Walking Distance, Quality of Life","Traditional Chinese Medicine",100
"CHICTR2000029493","http://www.chictr.org.cn/showproj.aspx?proj=48931",NA,"China","Hubei","2020-Feb","Not Recruiting","Randomized","Unspecified",2,"Resolved",NA,"Discharged","Adverse Events, 6-Minute Walking Distance, Quality of Life","Traditional Chinese Medicine",100
"NCT04261426","https://ClinicalTrials.gov/show/NCT04261426",NA,"China","Beijing","2020-Feb","Not Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Treatment-emergent Adverse Events","Ivig",80
"2020-001254-22","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001254-22/BE/",NA,"Belgium","Brussels","2020-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed",NA,"Hospitalized","Pneumonia or ARDS, Non-invasive Ventilation, IL-2, IL-7, Tumor Necrosis Factor (Any), Granulocyte Stimulaiting Factor, Interferon (Any), MCP-1, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings","Sargramostim",NA
"2020-001243-15","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001243-15/BE/",NA,"Belgium","Brussels","2020-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO","Itraconazole",NA
"2020-001236-10","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001236-10/NL/",NA,"Netherlands","Amsterdam","2020-Mar","Recruiting","Randomised","Single",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospitalization, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Monocyte Count, Lymphocyte Count, Erythrocyte Sedimentation Rate, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, Procalcitonin, Prothrombin, Fibrinogen, Coagulation Test, ALT, AST, Albumin, Bilirubin, PaO2-FiO2, SpO2","Imatinib mesilate",304
"2020-001335-28","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001335-28/NL/",NA,"Netherlands","Amsterdam","2020-Mar","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, Hospital Discharge, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Fever, Dyspnea, Treatment-emergent Adverse Events, Serious Adverse Events, White Blood Cell Count, ECG","IFX-1",130
"2020-001194-69","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001194-69/ES/",NA,"Spain","Madrid","2020-Apr","Recruiting","Randomised","Double",2,"Healthy","Non-severe","Healthy","Mortality, Viral Load or Clearance","Mefloquine",NA
"2020-001409-21","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001409-21/ES/",NA,"Spain","Madrid","2020-Apr","Recruiting","Randomised","Double",2,"Confirmed","Severe","ICU Or Hospitalized","Mortality, ICU Admission, Hospitalization, Clinical Improvement Score (Any), Organ Failure or Dysfunction (SOFA), Adverse Events, Serious Adverse Events","Defibrotide",NA
"2020-001307-16","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001307-16/ES/",NA,"Spain","Madrid","2020-Apr","Recruiting","Randomised","Open-Label",2,"Confirmed","Severe","ICU Or Hospitalized","Mortality, ICU Admission, Hospitalization, Invasive Mechanical Ventilation or ECMO","Corticosteroid(s)",NA
"2020-001052-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/ES/",NA,"Denmark","Copenhagen","2020-Apr","Recruiting","Randomised","Double",2,"Confirmed",NA,"Hospitalized","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, CK-MB, ALT, AST, Bilirubin","Remdesivir",440
"2020-001052-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/ES/",NA,"Germany","Berlin","2020-Apr","Recruiting","Randomised","Double",2,"Confirmed",NA,"Hospitalized","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, CK-MB, ALT, AST, Bilirubin","Remdesivir",440
"2020-001052-18","https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001052-18/ES/",NA,"Spain","Madrid","2020-Apr","Recruiting","Randomised","Double",2,"Confirmed",NA,"Hospitalized","Mortality, Hospitalization, Hospital Discharge, Clinical Improvement Score (Any), Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, White Blood Cell Count, Platelet Count, Hemoglobin, Creatinine Phosphokinase, CK-MB, ALT, AST, Bilirubin","Remdesivir",440
"IRCT20200128046294N2","http://en.irct.ir/trial/46463",NA,"Iran","Tehran","2020-Mar","Recruiting","Randomized","Single",2,"Confirmed","Mixed","Hospitalized","Mortality, Invasive Mechanical Ventilation or ECMO, Fever, Serious Adverse Events, SpO2, Respiratory Rate","Sofosbuvir",70
"IRCT20200316046792N1","http://en.irct.ir/trial/46554",NA,"Iran","Tehran","2020-Mar","Recruiting","Randomized","Double",3,"Confirmed",NA,"Hospitalized","Mortality, Hospitalization, Cough, Fever, Treatment-emergent Adverse Events, SpO2, Respiratory Rate","Corostop/Coroguard",150
"IRCT20200317046797N1","http://en.irct.ir/trial/46573",NA,"Iran","Tehran","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Mixed","Hospitalized","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Radiographic Findings","Camostat",40
"IRCT20160625028622N1","http://en.irct.ir/trial/46576",NA,"Iran","Tehran","2020-Mar","Completed","Non-Randomized","Double",2,"Confirmed",NA,"Mixed","Cough, SpO2, Radiographic Findings","Noscapine",125
"IRCT20140617018126N2","http://en.irct.ir/trial/46637",NA,"Iran","East Azarbaijan","2020-Mar","Completed","Randomized","Open-Label",2,"Confirmed","Unspecified","Hospitalized","C-Reactive Protein, White Blood Cell Count, Lymphocyte Count, SpO2, Respiratory Rate","Herbal medicine",60
"IRCT20160316027081N1","http://en.irct.ir/trial/46678",NA,"Iran","Fars","2020-Mar","Completed","Randomized","Double",2,"Confirmed","Unspecified","Hospitalized","Mortality, Hospital Discharge, Respiratory Rate","Herbal medicine",374
"IRCT20160310026998N11","http://en.irct.ir/trial/46690",NA,"Iran","East Azarbaijan","2020-Mar","Completed","Randomized","Open-Label",2,"Mixed","Mixed","Mixed","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO","Metformin",200
"IRCT20200323046841N1","http://en.irct.ir/trial/46715",NA,"Iran","Tehran","2020-Mar","Recruiting","Randomized","Triple",2,"Confirmed","Unspecified","Hospitalized","Clinical Improvement Score (Any)","Herbal medicine",60
"IRCT20180923041093N3","http://en.irct.ir/trial/46721",NA,"Iran","Tehran","2020-Mar","Recruiting","Randomized","Open-Label",2,"Confirmed","Unspecified","Outpatients","Mortality, Hospitalization, Cough, Fever, Other Mild Symptoms, Respiratory Rate","Herbal medicine",100
"IRCT20200317046797N2","http://en.irct.ir/trial/46786",NA,"Iran","Tehran","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Unspecified","Unclear","Mortality, Hospitalization, Invasive Mechanical Ventilation or ECMO, Cough, Dyspnea","Fingolimod",40
"IRCT20180802040678N4","http://en.irct.ir/trial/46824",NA,"Iran","Tehran","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Unspecified","Unclear","Mortality, Hospitalization, Clinical Improvement Score (Any)","Losartan",100
"IRCT20150704023055N2","http://en.irct.ir/trial/46837",NA,"Iran","Mazandaran","2020-Apr","Completed","Single-Arm","Open-Label",1,"Confirmed","Severe","ICU Or Hospitalized","Clinical Improvement Score (Any), IL-6","Extracorporeal Blood Purification",10
"JPRN-JRCT2031190264","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031190264",NA,"United States","Washington, Dc","2020-Mar","Recruiting","Randomized","Unspecified",NA,"Confirmed","Mixed","Mixed",NA,"Remdesivir",100
"JPRN-JRCT2031190264","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031190264",NA,"South Korea","Seoul","2020-Mar","Recruiting","Randomized","Unspecified",NA,"Confirmed","Mixed","Mixed",NA,"Remdesivir",100
"JPRN-JRCT2031190264","https://rctportal.niph.go.jp/en/detail?trial_id=JRCT2031190264",NA,"Japan","Toyama","2020-Mar","Recruiting","Randomized","Unspecified",NA,"Confirmed","Mixed","Mixed",NA,"Remdesivir",100
"JPRN-JRCTS031190227","https://rctportal.niph.go.jp/en/detail?trial_id=JRCTS031190227",NA,"Japan","Gunma","2020-Feb","Recruiting","Unspecified","Open-Label",NA,"Confirmed",NA,"Hospitalized","Viral Load or Clearance, C-Reactive Protein","HCQ ,  LPV/R ,  Oseltamivir",50
"JPRN-JRCTS031190269","https://rctportal.niph.go.jp/en/detail?trial_id=JRCTS031190269",NA,"Japan","Toyama","2020-Mar","Recruiting","Randomized","Open-Label",NA,"Yes","Unspecified","Unclear","Viral Load or Clearance, Pneumonia or ARDS, Adverse Events, Treatment-emergent Adverse Events, Serious Adverse Events","Ciclesonide",90
"DRKS00021300","https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00021300",NA,"Germany","Baden-Wurttemberg","2020-Apr","Recruiting","Randomized","Open-Label",2,"Confirmed","Severe","Hospitalized","Mortality, ICU Admission, IL-6","Ecmo",30
"CHICTR2000029381","http://www.chictr.org.cn/showproj.aspx?proj=48768",NA,"China","Guangdong","2020-Jan","Not Recruiting","Non-Randomized","Unspecified",2,"Confirmed",NA,"Hospitalized","ICU Admission, Hospitalization, Viral Load or Clearance, Pneumonia or ARDS, Invasive Mechanical Ventilation or ECMO, Organ Failure or Dysfunction (SOFA), C-Reactive Protein, White Blood Cell Count, Creatinine Phosphokinase, CK-MB, eGFR, Myoglobin, Troponin, ALT, AST, Albumin, Bilirubin, IgG, IgM or IgA, Blood Gas, PaO2-FiO2, SpO2, Respiratory Rate, Radiographic Findings","Traditional Chinese Medicine",400
"CHICTR2000030215","http://www.chictr.org.cn/showproj.aspx?proj=50107",NA,"China","Jiangxi","2020-Feb","Not Recruiting","Randomized","Unspecified",6,"Confirmed","Mixed",NA,"Viral Load or Clearance, Fever, C-Reactive Protein, Erythrocyte Sedimentation Rate, CD4, Respiratory Rate, Radiographic Findings","Traditional Chinese Medicine",120
"CHICTR2000029386","http://www.chictr.org.cn/showproj.aspx?proj=48777",NA,"China","Chongqing","2020-Jan","Recruiting","Randomized","Unspecified",2,"Confirmed","Severe","Hospitalized","Mortality, Hospitalization, Clinical Improvement Score (Any), Invasive Mechanical Ventilation or ECMO","Corticosteroid(s)",48
"CHICTR2000030503","http://www.chictr.org.cn/showproj.aspx?proj=49632",NA,"China","Zhejiang","2020-Mar","Recruiting","Non-Randomized","Unspecified",2,NA,NA,NA,"Mortality, ICU Admission, Clinical Improvement Score (Any), Viral Load or Clearance, Pneumonia or ARDS, IL-6, PaO2-FiO2","Extracorporeal Blood Purification",60
"CHICTR2000029573","http://www.chictr.org.cn/showproj.aspx?proj=49065",NA,"China","Zhejiang","2020-Feb","Recruiting","Randomized","Unspecified",4,NA,NA,NA,"Mortality, Viral Load or Clearance, Pneumonia or ARDS, Radiographic Findings","Cytokine Protein Injection",480
"NCT04337216","https://clinicaltrials.gov/show/NCT04337216",NA,"United States","Washington, Dc","2020-Jan","Not Recruiting","Single-Arm","Open-Label",1,"Confirmed","Mixed","Hospitalized",NA,"Mavrilimumab",10
"NL8491","https://trialregister.nl/trial/8491",NA,"Netherlands","Amsterdam","2020-Mar","Recruiting","Randomized","Double",2,"Confirmed","Severe",NA,"Mortality, ICU Admission, Viral Load or Clearance, Non-invasive Ventilation, Invasive Mechanical Ventilation or ECMO, Adverse Events, Serious Adverse Events, Albumin, PaO2-FiO2, SpO2","Imatinib",386
